The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 9, 2016, is named 140030US01_Corrected_SL and is 51 kilobytes in size.
The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP).
It has been known for a long time that when traditional insulin is used to treat diabetes, it is associated with an increase in body weight. Insulin has to be injected subcutaneously up to several times per day. Thus, an antidiabetic therapeutic approach should not only lower fasting and postprandial blood glucose levels but optimally also induce weight loss. Type 2 diabetes is generally treated in the early phases with diet and exercise. As the condition progresses, various oral anti-diabetic agents are added. Novel hormone-based therapies for type 2 diabetes are now emerging resembling an endogenous mode of action, such as glucagon like peptide (GLP)-1 and amylin analogues. These agents do not only improve glucose homeostasis but also very promisingly exert beneficial effects on body weight. In obese individuals, fasting amylin concentrations are elevated in conjunction with hyperinsulinemia and in patients with type 2 diabetes, amylin, like insulin, is relatively deficient depending on the severity of β-cell secretory failure. Amylin receptor agonists are useful in reducing food intake and treating obesity. Human amylin is a 37 amino acid long polypeptide which has physico-chemical properties that make its use as a drug troublesome. In particular, it has a tendency for fibrillogenesis, i.e. the formation of fibrils, in vitro and/or ex vivo and becomes ineffective due to precipitation. Pramlintide is a drug product marketed by Amylin Pharmaceuticals as Symlin® and a human amylin analogue and receptor agonist used in the treatment of diabetes as an add-on to insulin. Pramlintide is chemically unstable at neutral pH and it is therefore provided in an acidic solution.
The calcitonin receptor is found in many tissues throughout the body and it is believed to be involved in regulation of bone metabolism. Salmon calcitonin is currently sold under the tradename Miacalcic®. The product is used against hypercalcaemia, osteoporosis (including post-menopausal osteoporosis and glucocorticoid-related osteoporosis), ostitis deformans (Pagets disease) and is administered once daily either by injection or nasally. The calcitonin is bound to specific receptors in the membrane of the skeleton, the kidneys and in the central nervous system (CNS). Calcitonin is chemically unstable at neutral pH and it is therefore provided in an acidic solution.
Polypeptides with activity at both the amylin and calcitonin receptor and the amylin receptor may be advantageous; however increased half-life of amylin and calcitonin receptor agonists would highly increase the usability and convenience for the use as a medicament in treating the above mentioned diseases. A further drawback of the currently known pool of calcitonin and amylin peptides is that they are only chemically stable in solution when handled in a narrow acidic pH range, which makes them bothersome to handle under circumstances were a broader range of pH is desired. Thus polypeptides which are amylin and/or calcitonin receptor agonists with more flexible solubility profiles would increase the usability in medicinal products.
The invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof and pharmaceutical compositions comprising SEQ ID NO: 1, analogues or derivatives thereof.
Further this invention relates to derivatives, pharmaceutical formulations, co-formulations and co-treatments of such mimylin peptides or derivatives in combination with GLP-1 compounds and the use thereof as medicaments in the treatment of diabetes, overweight, obesity or neuropathic pain.
In some embodiments the present invention relates to a mimylin peptide comprising a sequence having at least 66% sequence identity to SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises up to 11 amino acid modifications relative to SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises up to 11 amino acid modifications in one or more of the positions 1, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 27, 28, 30, 31, 32 relative to SEQ ID NO: 1, wherein the amino acid numbering corresponds to SEQ ID NO: 1.
In some embodiments the present invention relates to a mimylin peptide comprising a sequence having at least 66% sequence identity to SEQ ID NO: 1 and c-terminal amide group.
In some embodiments the present invention relates to a mimylin peptide comprising a sequence having at least 66% sequence identity to SEQ ID NO: 1 and no disulfide bridge. In some embodiments the present invention relates to a mimylin peptide comprising a sequence having at least 66% sequence identity to SEQ ID NO: 1 and comprises no cysteins in certain positions, preferably no cysteins in position 2 and/or 8, wherein the amino acid numbering corresponds to SEQ ID NO: 1.
In some embodiments the mimylin peptides of the present invention have less than 60% sequence identity to known amylin and calcitonin receptor agonists. However, the inventors surprisingly found that mimylin peptides are agonists to the amylin and calcitonin receptors and show a favourable solubility profile throughout the complete pH scale, especially at neutral pH and above, i.e. from about pH 6.0 and above, preferably from about pH 7.0 and above. Further the peptides of the present invention are very stable peptides and thus potentially very useful for use in medicaments. Furthermore mimylin has a low Immunogenicity Risk Score (IRS). It was surprisingly found that the mimylin compounds of this invention are able to be combined with GLP-1 compounds in co-formulations wherein both remain stable. It was surprisingly found that the mimylin compounds of this invention are able to be combined with GLP-1 compounds in formulations at pH between about 7.0 and 8.5 wherein both remain stable. It was further surprisingly found that co-administration in DIO rats of a compound according to this invention and liraglutatide enhanced the weight-loss achieved by the liraglutide treatment alone, surpassing an add-on effect. Further studies are ongoing. It was surprisingly found that compounds of this invention do not affect the PK profile of liraglutide, and liraglutide does surprisingly not affect the PK profile of compounds of this invention when administered as co-formulations to LYD pigs. It was surprisingly found that Ex. compound 2 or 46 of this invention do not affect the PK profile of liraglutide and liraglutide does surprisingly not affect the PK profile of Ex. compound 2 or 46 of this invention when administered as co-formulations to LYD pigs.
The invention may also solve further problems that will be apparent from the disclosure of the exemplary embodiments and aspects.
The invention relates to mimylin peptides comprising an amino acid sequence which is a mimylin analogue (EASELSTAALGRLSAELHELATLPRTETGPESP) or analogues or derivatives thereof which all show agonist effects on the amylin receptor. Further this invention relates to derivatives, pharmaceutical compositions comprising of such mimylin peptides and the use of such mimylin peptides as medicaments.
In some embodiments the mimylin peptides of the present invention are agonists to the calcitonin receptor. In some embodiments the mimylin peptide of the present invention agonises the human amylin and human calcitonin receptors and shows solubility throughout the complete pH scale, preferably neutral pH and above.
In some embodiments a mimylin peptide according to the present invention comprises up to 11 amino acid modifications relative to SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises up to 11 amino acid modifications relative to SEQ ID NO: 1, wherein in one or more of the positions 1, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 27, 28, 30, 31, 32, wherein the amino acid numbering corresponds to SEQ ID NO: 1.
In some embodiments the present invention relates to a mimylin peptide comprising a sequence having at least 66% sequence identity to SEQ ID NO: 1 and a c-terminal amide group.
In some embodiments the present invention relates to a mimylin peptide comprising a sequence having at least 66% sequence identity to SEQ ID NO: 1 and no disulfide bridge. In some embodiments the present invention relates to a mimylin peptide comprising a sequence having at least 66% sequence identity to SEQ ID NO: 1 and comprises no cysteins, preferably in position 2 and/or 8, wherein the amino acid numbering corresponds to SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 50 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 20 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 19 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 18 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 17 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 16 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 15 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 14 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 13 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 12 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 11 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 10 pM or less. In some embodiments a mimylin peptide according to the present invention has an EC50 in a human amylin receptor functional assay (tested as disclosed in Assay IIb) of about 5 pM or less.
In some embodiments a mimylin peptide according to the present invention is a peptide comprising SEQ ID NO: 2;
wherein X represents amino acids and wherein
X(−1) is E or no amino acid,
X1 is selected from the group consisting of E or A or no amino acid,
X2 is selected from the group consisting of L, A or P,
X3 is selected from the group consisting of S or P
X4 is selected from the group consisting of E, P, K, Q or G
X5 is selected from the group consisting of L, V, or I,
X8 is selected from the group consisting of L or A,
X9 is selected from the group consisting of A, V, I, S or T,
X10 is selected from the group consisting of L, A, I, H or V,
X12 is selected from the group consisting of R, H or K,
X14 is selected from the group consisting of S, T or E,
X15 is selected from the group consisting of A, Q, E, e or T,
X16 is selected from the group consisting of R, E, K or Q,
X17 is selected from the group consisting of L or I,
X18 is selected from the group consisting of H or A,
X19 is selected from the group consisting of E, R or K,
X20 is selected from the group consisting of L, I or V,
X21 is selected from the group consisting of A, Q, S, E or T,
X23 is selected from the group consisting of T, Y or L,
X25 is selected from the group consisting of R, P, H or K,
X27 is selected from the group consisting of E, Q, G or K,
X28 is selected from the group consisting of T or P,
X30 is selected from the group consisting of P, S or T,
X31 is selected from the group consisting of E, Q, G, A, P or K,
X32 is selected from the group consisting of T, S, H, P or A and
X34 is G or no amino acid
In some embodiments a mimylin peptide according to the present invention is a peptide comprising SEQ ID NO: 3;
wherein X represents amino acids and wherein
X1 is selected from the group consisting of E or A or no amino acid,
X2 is selected from the group consisting of L, A or P,
X3 is selected from the group consisting of S or P
X4 is selected from the group consisting of E, P, K, Q or G
X5 is selected from the group consisting of L, V, or I,
X8 is selected from the group consisting of L or A,
X9 is selected from the group consisting of A, V, I, S or T,
X10 is selected from the group consisting of L, A, I, H or V,
X12 is selected from the group consisting of R, H or K,
X14 is selected from the group consisting of S, T or E,
X15 is selected from the group consisting of A, Q, E, e or T,
X16 is selected from the group consisting of R, E, K or Q,
X17 is selected from the group consisting of L or I,
X18 is selected from the group consisting of H or A,
X19 is selected from the group consisting of E, R or K,
X20 is selected from the group consisting of L, I or V,
X21 is selected from the group consisting of A, Q, S, E or T,
X23 is selected from the group consisting of T, Y or L,
X25 is selected from the group consisting of R, P, H or K,
X27 is selected from the group consisting of E, Q, G or K,
X28 is selected from the group consisting of T or P,
X30 is selected from the group consisting of P, S or T,
X31 is selected from the group consisting of E, Q, G, A, P or K,
X32 is selected from the group consisting of T, S, H, P or A,
X34 is G or no amino acid
X35 is T or no amino acid and
X36 is Y or no amino acid.
In some embodiments a mimylin peptide according to the present invention is a peptide comprising SEQ ID NO: 4;
wherein X represents amino acids and wherein
X1 is selected from the group consisting of E or A or no amino acid,
X2 is selected from the group consisting of L, A or P,
X3 is selected from the group consisting of S or P
X4 is selected from the group consisting of E, P, K, Q or G
X5 is selected from the group consisting of L, V, or I,
X8 is selected from the group consisting of L or A,
X9 is selected from the group consisting of A, V, I, S or T,
X10 is selected from the group consisting of L, A, I, H or V,
X12 is selected from the group consisting of R, H or K,
X14 is selected from the group consisting of S, T or E,
X15 is selected from the group consisting of A, Q, E, e or T,
X16 is selected from the group consisting of R, E, K or Q,
X17 is selected from the group consisting of L or I,
X18 is selected from the group consisting of H or A,
X19 is selected from the group consisting of E, R or K,
X20 is selected from the group consisting of L, I or V,
X21 is selected from the group consisting of A, Q, S, E or T,
X23 is selected from the group consisting of T, Y or L,
X25 is selected from the group consisting of R, P, H or K,
X27 is selected from the group consisting of E, Q, G or K,
X28 is selected from the group consisting of T or P,
X30 is selected from the group consisting of P, S or T,
X31 is selected from the group consisting of E, Q, G, A, P or K,
X32 is selected from the group consisting of T, S, H, P or A and
In some embodiments a mimylin peptide according to this invention can be a peptide SEQ ID NO: 2, 3 or 4, wherein an additional amino acid is added to the N-terminal. In some embodiments a mimylin peptide according to this invention can be a peptide SEQ ID NO: 2, 3 or 4, wherein an additional amino acid is added to the N-terminal, wherein said additional amino acid is E.
In some embodiments a mimylin peptide according to this invention can be described according to any one of the SEQ ID NO: 2, 3 or 4, wherein said mimylin peptide is derivatised with a side chain in the alpha amino group of the N-terminal amino acid, wherein said side chain comprises a protracting moiety as defined in the present invention and optionally comprises a linker.
For some embodiments, the mimylin peptide has a substituent on one amino acid residue, which amino acid residue is either the amino acid residue in the N-terminal residue or the amino acid residue is a Lysine, wherein said lysine can be at any of the positions 1-33 according to the numbering of SEQ ID NO: 1.
For some embodiments, the mimylin peptide has a substituent on the N-terminal amino acid residue bound via the α(alpha)-amino group of the N-terminal amino acid residue.
For some embodiments, the N-terminal amino acid residue is Lysine and the mimylin peptide has a substituent on the N-terminal amino acid residue bound via the ε(epsilon)-amino group of the lysine amino residue.
For some embodiments, the mimylin peptide is extended by addition of a Lysine residue at the N-terminal and the mimylin peptide has a substituent on the N-terminal amino acid residue bound via the E-amino group of the lysine amino residue.
For some embodiments, the mimylin peptide is extended by addition of a Glutamic acid residue at the N-terminal and the mimylin peptide has a substituent on the N-terminal amino acid residue bound via the a-amino group of the lysine amino residue.
For some embodiments, the mimylin peptide is extended by addition of an amino acid residue at the N-terminal and the mimylin peptide has a substituent on the N-terminal amino acid residue bound via the a-amino group of the N-terminal amino acid residue.
In some embodiments an amylin derivative is produced by derivatising a mimylin peptide with a side chain attached in the N-terminal of said mimylin peptide. In some embodiments an amylin derivative is produced by derivatising a mimylin peptide with a side chain attached at a K (Lys) within the sequence of said mimylin peptide. In some embodiments such attachment at a K (Lys) can be in position 4, 12, 16, 23, 18, 27 or 34.
In some embodiments SEQ ID NO: 2, 3 or 4 are analogues of SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is up to 11 amino acids different from SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is up to 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1, preferably 1, 2 or 3, more preferably 4, 3 or 5 amino acids different from SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is up to 5 amino acids different from SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is up to 4 amino acids different from SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is up to 3 amino acids different from SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is up to 2 amino acids different from SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is 1 amino acid different from SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 22 amino acids identical with SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 23 amino acids identical with SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 24 amino acids identical with SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 25 amino acids identical with SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 26 amino acids identical with SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 27 amino acids identical with SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 28 amino acids identical with SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 29 amino acids identical with SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 30 amino acids identical with SEQ ID NO: 1. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 31 amino acids identical with SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein the sequence is at least 32 amino acids identical with SEQ ID NO: 1.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4 and a c-terminal amide group. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is E. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is E and the mimylin peptide is derivatised with a side chain attached to the mimylin peptide at the N-terminal. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is E and the mimylin peptide is derivatised with a side chain attached to the mimylin peptide at the N-terminal, wherein said side chain comprises a protracting moiety and a linker. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is E and the mimylin peptide is derivatised with a side chain attached to the mimylin peptide at the N-terminal, wherein said side chain comprises a protracting moiety and no linker.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is A. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is A and the mimylin peptide is derivatised with a side chain attached to the mimylin peptide at the N-terminal. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is A and the mimylin peptide is derivatised with a side chain attached to the mimylin peptide at the N-terminal, wherein said side chain comprises a protracting moiety and a linker.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is any amino acid except E. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is any amino acid except E and the mimylin peptide is derivatised with a side chain attached to the mimylin peptide at the N-terminal. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X1 is any amino acid except E and the mimylin peptide is derivatised with a side chain attached to the mimylin peptide at the N-terminal, wherein said side chain comprises a protracting moiety and a linker. In particular embodiments, the side chain and/or the protracting moiety are lipophilic, and/or negatively charged at physiological pH (pH about 7.4).
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X2 is L. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X2 is A. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X2 is P.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X3 is S. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X3 is P.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X4 is L. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X4 is A.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X5 is L. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X5 is L. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X5 is V.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X7 is T.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X8 is L. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X8 is A.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X9 is A. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X9 is V. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X9 is I. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X9 is S. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X9 is T. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X9 is L.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X10 is L. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X10 is A. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X10 is V. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X10 is I.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X12 is R. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X12 is H. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X12 is K.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X15 is A. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X15 is Q. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X15 is E. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X15 is e, wherein e is the d-isoform of Glutamic acid. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X15 is T.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X19 is E. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X19 is R. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X19 is K.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X20 is L. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X20 is I. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X20 is V.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X21 is A. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X21 is Q. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X21 is S. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X21 is S. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X21 is E. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X21 is T.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X23 is Y. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X23 is L.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X27 is E. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X27 is Q. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X27 is G. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X27 is K.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X30 is P. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X20 is S. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X30 is T.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X31 is E. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X31 is Q. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X31 is G. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X31 is A. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X31 is P. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X31 is K.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X32 is T. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X32 is S. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X32 is H. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X32 is P. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X32 is A.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X33 is Y. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X33 is S. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X16 is H. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X33 is F. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X16 is L. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X33 is S. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X33 is G. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X33 is A.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2 or 3, wherein X34 is R. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2 or 3, wherein X34 is deleted.
In some embodiments the mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein one or all of X5, X10, X13, X17, X20 and X23 are L. In some embodiments the mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein at least four of X5, X10, X13, X17, X20 and X23 are L. In some embodiments the mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein at least three of X5, X10, X13, X17, X20 and X23 are L.
In some embodiments the mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein X12 and/or X25 is R. In some embodiments the mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, wherein one or all of X5, X10, X13, X17, X20 and X23 are L and wherein X12 and/or X25 is R.
In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, which does not comprise any N. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, which does not comprise any Q. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, which does not comprise any C. In some embodiments a mimylin peptide according to the present invention comprises a sequence according to SEQ ID NO: 2, 3 or 4, which does not comprise any disulfide bridges.
In some embodiments a mimylin derivative according to this invention is represented by the compounds listed in Table 1. The compound names as used herein are listed in Table 1 indicating the modifications relative to SEQ ID NO: 1 (also designated mimylin herein) and the side chain as well as the site of attachment of the side chain to the mimylin peptide. Table 1 discloses the compound number (EX. #) and the compound name. Table 2 indicates the modifications relative to mimylin in the mimylin peptides, i.e. the mimylin peptides, which are derivatised with a side chain to the mimylin derivatives listed in Table 1. Ex. #1 in Table 1 is SEQ ID NO: 1 and is not derivatised as also indicated by the name.
In some embodiments a mimylin peptide according to this invention is represented by the compounds listed in Table 2, wherein Table 2 indicates the amino acid modifications relative to SEQ ID NO: 1, also designated mimylin. Table 2 indicates the modifications relative to mimylin in the mimylin peptides, i.e. the mimylin peptides, which are derivatised with a side chain to form the mimylin derivatives listed in Table 1. Table 2 represents the mimylin analogues which have been derivatised, resulting in the corresponding mimylin derivative represented in Table 1. Thus the compound in EX. #8 in Table 1 or 3, respectively is a derivative of a mimylin analogue which has been modified with the amino acids as indicated in Table 2 or 4 as Ex. #8bb
In some embodiments a mimylin derivative comprising a mimylin peptide with up to 11 amino acid modifications relative to SEQ ID NO: 1 (mimylin) according to this invention is represented by the compounds listed in Table 3. Table 2 and 4 respectively, represent the mimylin analogues which have been derivatised, resulting in the corresponding mimylin derivative represented in Table 1 or 3 respectively. Thus the compound in EX. #8 in Table 1 or 3, respectively is a derivative of a mimylin analogue which has been modified with the amino acids as indicated in Table 2 or 4 as Ex. #8bb.
In some embodiments a mimylin peptide with up to 11 amino acid modifications relative to SEQ ID NO: 1 (mimylin) according to this invention is represented by the compounds listed in Table 4. Thus the compound in Ex. #8 in Table 1 or 3, respectively is a derivative of a mimylin analogue which has been modified with the amino acids as indicated in Table 2 or 4 as Ex. #8bb.
I one embodiment the mimylin derivatives of this invention can be presented by their structure formula as presented in Table 5.
In some embodiments the invention relates to a method for weight management making use of a mimylin peptide or derivative a pharmaceutical formulation, co-formulation or co-treatment of any one of the non-limiting numbered aspects of this invention. In some embodiments the invention relates to a method for reduction of appetite making use of a mimylin peptide or derivative a pharmaceutical formulation, co-formulation or co-treatment of any one of the non-limiting numbered aspects of this invention. In some embodiments the invention relates to a method for reduction of food intake making use of a mimylin peptide or derivative a pharmaceutical formulation, co-formulation or co-treatment of any one of the non-limiting numbered aspects of this invention.
In some embodiments the invention relates to a method for treatment or prevention of obesity making use of a mimylin peptide or derivative a pharmaceutical formulation, co-formulation or co-treatment of any one of the non-limiting numbered aspects of this invention. In some embodiments the invention relates to use of a mimylin peptide or derivative or a pharmaceutical formulation, co-formulation or co-treatment according to the non-limiting numbered aspects of this invention for treatment or prevention of obesity. In some embodiments the subject suffering from obesity is human, such as an adult human or a paediatric human (including infants, children, and adolescents). A human subject suffering from obesity may have a BMI of ≧30; this subject may also be referred to as obese. In some embodiments the human subject suffering from obesity may have a BMI of ≧35 or a BMI in the range of ≧30 to <40. In some embodiments the obesity is severe obesity or morbid obesity, wherein the human subject may have a BMI of ≧40.
In some embodiments the invention relates to a method for treatment or prevention of overweight making use of a mimylin peptide or derivative a pharmaceutical formulation, co-formulation or co-treatment of any one of the non-limiting numbered aspects of this invention, optionally in the presence of at least one weight-related comorbidity. In some embodiments the invention relates to use of the a mimylin peptide or derivative or a pharmaceutical formulations, co-formulation or co-treatment according to the non-limiting numbered aspects of this invention for treatment or prevention of overweight, optionally in the presence of at least one weight-related comorbidity. In some embodiments the subject suffering from overweight is human, such as an adult human or a paediatric human (including infants, children, and adolescents). In some embodiments a human subject suffering from overweight may have a BMI of ≧25, such as a BMI of ≧27. In some embodiments a human subject suffering from overweight has a BMI in the range of 25 to <30 or in the range of 27 to <30. In some embodiments the weight-related comorbidity is selected from the group consisting of hypertension, diabetes (such as type 2 diabetes), dyslipidaemia, high cholesterol, and obstructive sleep apnoea.
In some embodiments the invention relates to a method for reduction of body weight making use of a mimylin peptide or derivative a pharmaceutical formulation, co-formulation or co-treatment of any one of the non-limiting numbered aspects of this invention. In some embodiments the invention relates to use of a mimylin peptide or derivative or a pharmaceutical formulations according to the non-limiting numbered aspects of this invention for reduction of body weight. A human to be subjected to reduction of body weight according to the present invention may have a BMI of such as a BMI of 27 or a BMI of 30. In some embodiments the human to be subjected to reduction of body weight according to the present invention may have a BMI of or a BMI of 40. The term “reduction of body weight” may include treatment or prevention of obesity and/or overweight.
position 33 can be modified to Y, H, F, L, S, G or A, preferably Y.
549. The mimylin derivative according to any one of the preceding aspects 163-515, wherein said derivative has an EC50 in a human amylin receptor functional Assay IIb of about 800 pM or less.
A receptor agonist may be defined as a peptide or analogue that binds to a receptor and elicits a response typical of the natural ligand. A full agonist may be defined as one that elicits a response of the same magnitude as the natural ligand (see e.g. “Principles of Biochemistry”, A L Lehninger, D L Nelson, M M Cox, Second Edition, Worth Publishers, 1993, page 763).
Thus, for example, an “Amylin receptor agonist” may be defined as a compound which is capable of binding to the Amylin receptor and capable of activating it. And a “full” amylin receptor agonist may be defined as an Amylin receptor agonist which is capable of eliciting a magnitude of Amylin receptor response that is similar to native amylin. An Amylin receptor agonist will often also be a calcitonin receptor agonist. Examples of Amylin receptor agonists are human amylin, pramlintide and calcitonin.
The term “human amylin” as used herein relates to the polypeptide human amylin having the sequence
which structure can be shown as
The term “pramlintide” as used herein relates to the peptide having the sequence
which structure can be shown as
Pramlintide has a disulfide bridge between the two Cys residues and a C-terminal amide group.
The term “calcitonin” means salmon calcitonin or human calcitonin.
The term “salmon calcitonin” or “sCT” means the native protein sequence of salmon calcitonin as disclosed in Niall et al (1969), Biochemistry vol 64,
which structure can be shown as
It has a disulfide bridge between the first and seventh amino acids at the amino-terminal end of the polypeptide chain and a prolinamide group at the carboxyl terminal amino acid being essential for its biological activity.
The term “human calcitonin” means the native protein sequence of human calcitonin as disclosed in Niall et al (1969), Biochemistry vol 64,
which structure can be shown as
It has a disulfide bridge between the first and seventh amino acids at the amino-terminal end of the polypeptide chain, the disulfide bridge being essential for its biological activity, and a prolinamide group at the carboxyl terminal amino acid.
The term “mimylin” as used herein refers to the protein with the sequence
Mimylin is a novel amylin and calcitonin receptor agonist, with less than 60% sequence identity to salmon calcitonin and has no disulfide bridges.
The term “analogue” as used herein describes a peptide comprising one or more amino acid modifications, such as but not limited to substitution and/or one or more deletion and/or one or more addition of any one of the amino acid residues for any natural or unnatural amino acid, synthetic amino acids or peptidomimetics and/or the attachment of a side chain to any one of the natural or unnatural amino acids, synthetic amino acids or peptidomimetics at any available position. The addition or deletion of amino acid residues can take place at the N-terminal of the peptide and/or at the C-terminal of the peptide.
Thus the term “mimylin analogue” or “analogue of mimylin” as used herein refers to a peptide, wherein one or more amino acids have been modified relative to SEQ ID NO: 1. The term “mimylin peptide” as used herein refers to the group of compounds comprising mimylin or an analogue thereof. The term “mimylin peptide” will thus also cover the term “backbone” and “polypeptides”.
When used herein the term “natural amino acid” is an amino acid (with the usual three letter codes & one letter codes in parenthesis) selected from the group consisting of: Glycine (Gly & G), proline (Pro & P), alanine (Ala & A), valine (Val & V), leucine (Leu & L), isoleucine (Ile & I), methionine (Met & M), cysteine (Cys & C), phenylalanine (Phe & F), tyrosine (Tyr & Y), tryptophan (Trp & W), histidine (His & H), lysine (Lys & K), arginine (Arg & R), glutamine (Gln & Q), asparagine (Asn & N), glutamic acid (Glu & E), aspartic acid (Asp & D), serine (Ser & S) and threonine (Thr & T). If anywhere in this invention reference is made to a mimylin peptide, analogue or derivative or peptides according to this invention comprising or not comprising G, P, A, V, L, I, M, C, F, Y, H, K, R, Q, N, E, D, S or T, without specifying further, amino acids are meant. If not otherwise indicated amino acids indicated with a single letter code in CAPITAL letters indicate the L-isoform, if however the amino acid is indicated with a lower case letter, this amino acid is used/applied as it's D-form.
If, due to typing errors, there are deviations from the commonly used codes, the commonly used codes apply. The amino acids present in the mimylin peptides of the present invention are, preferably, amino acids which can be coded for by a nucleic acid.
If the analogue contains either more than 33 amino acid residues or less than 33 amino acid residues then the skilled person can still align that sequence with the sequence of mimylin (SEQ ID NO: 1) to determine the placement number of the corresponding, respective amino acid residue. A method for determination of “sequence identity” between two analogues the two peptides mimylin and [23Y, 30S, 31G]mimylin (i.e. EX. #24bb) are aligned. The sequence identity of the mimylin analogue relative to mimylin is given by the number of aligned identical residues minus the number of different residues divided by the total number of residues in mimylin (i.e. SEQ ID NO: 1) Accordingly, in said example the sequence identity is (33-3)/33. A suitable alignment program can be tested with a suitable alignment program is “needle”, which is a Needleman-Wunsch alignment. The alogorithm for this alignment program is described in Needleman, S. B. and Wunsch, C. D., (1970), Journal of Molecular Biology, 48: 443-453.
In the numbering sequence of SEQ ID NO: 1, and according to established practice in the art, the amino acid residue at the N-terminal Glutamic acid (E) is assigned no. 1 and subsequent amino acid residues are numbered consecutively, ending at the C-terminal with proline (P) assigned no. 33. Therefore, generally, any reference herein to position number of an amino acid residue provides its location in a 33 amino acid sequence; said 33 amino acid sequence being an analogue of mimylin. For example, a reference to an analogue modified at position 14 may refer to an analogue wherein the 14th amino residue out of the 33 amino acids in the analogue has been modified.
In other words, the amino acid sequence numbering of the analogue provides the position of each analogue with respect to a 33 amino acid sequence, wherein the numbering is consecutive and ascending in the direction from the N-terminal to the C-terminal.
Analogues may be described by reference to the number of the amino acid residue in mimylin (SEQ ID NO: 1) which is modified, i.e. by its position, and the nature of the modification. The following are non-limiting examples of appropriate analogue nomenclature. For example:
[I9]-mimylin designates a mimylin analogue (mimylin) wherein the change from mimylin is the substitution of A position 9 with I, such as in example compound 10. One example can also be the designation des1 in relation to an analogue of mimylin, which refers to an analogue in which the N-terminal amino acid, Glutamic acid, has been deleted. An analogue of mimylin, where the N-terminal amino acid has been deleted may also be designated des1 mimylin.
[des1, 4K, 30S, 31G]mimylin designates a mimylin analogue (mimylin), in which the E at position 1 has been deleted and E in position 4 had been substituted with K, P in position 30 with S and E in position 31 with G.
If an additional amino acid, such as Glutamic acid (E) is added to the N-terminal in the position before position 1, the amino acid change will be indicated as −1E, because no position 0 exist. In the aspects this may be described with the term that no amino acid is present in position −1, thus he term “no amino acid” as used herein is equivalent to the term “absent”, which means that the position to which reference is made simply does not comprise any amino acid residue.
Thus the analogue of the derivative of compound 83 (EX. #83) is denominated as follows: [−1E, 1A, 23Y, 30S, 31G]mimylin and thus discloses a sequence in which E is added to the N-terminal amino acid, the N-terminal amino acid is modified from an E to A, P of position 30 in SEQ ID NO: 1 is substituted with S and E in position 31 of SEQ ID NO: 1 is substituted with G.
In mimylin peptides, such as EX. #130bb the indication of 23aQ, 23bT, 23cY means, that QTY has been inserted between amino acid position 23 and position 24 relative to the numbering of SEQ ID NO: 1 and the amino acid in position 23 is the original amino acid; L. The sequence of the mimylin peptide 1300bb is thus;
As is apparent from the above examples, amino acid residues may be identified by their full name, their one-letter code, and/or their three-letter code. These three ways are fully equivalent.
The expressions “conforms to”, “corresponds to”, “a position equivalent to” or “corresponding position” as used herein may be used to characterise the site of modification in an analogue of mimylin by reference to SEQ ID NO: 1. Equivalent, identical or corresponding positions are easily deduced, e.g. by simple handwriting and eyeballing; and/or a standard protein or mimylin peptide alignment program may be used, such as “needle” which is a Needleman-Wunsch alignment. The algorithm is described in Needleman, S. B. and Wunsch, C. D., (1970), Journal of Molecular Biology, 48: 443-453, and the align program by Myers and W. Miller in “Optimal Alignments in Linear Space” CABIOS (computer applications in the biosciences) (1988) 4:11-17. For the alignment, the default scoring matrix BLOSUM62 and the default identity matrix may be used, and the penalty for the first residue in a gap may be set at −10 and the penalties for additional residues in a gap at −0.5.
Naming the derivatives herein was performed as follows:
[Y(C)aa1X(S)aa2]P (Formula 1), wherein P is the peptide (such as for example mimylin), aa1 and aa2 describe one, more or no amino acid modifications of said peptide, (S) discloses the side chain which is attached to the peptide and X describes the attachment site. X in formula 1 can thus indicate N-terminal, when the side chain (S) is attached in the N-terminal or a specific position such as K4, which then exemplified for a mimylin derivative would refer to a substitution of the amino acid E with K in position 4 corresponding to SEQ ID NO: 1, to which the side chain (S) is attached. Y(C) in formula 1 may be placed throughout the sequence, wherever relevant and indicates if additional modifications to the amino acid sequence of chemical nature are present; Y indicates the placement, so “c-terminal (−)” indicates that the chemical change is present in the c-terminal. The (−) of “c-terminal (−) means “acid”, thus “c-terminal(−)” means c-terminal acid. The if “N-terminal(acetyl)” is mentioned in the naming this means that and acetyl
is present at the N-terminal instead of the regular alpha amino group. If C is “c-terminal (−)” the c-terminal end of the peptide is a c-terminal acid instead of a c-terminal amide. If no indication of “c-terminal (−)” is made in the derivative name, the c-terminal of the derivatives according to the present invention are c-terminal amides.
The following are non-limiting examples of appropriate derivative nomenclature. [N-terminal(C18diacid-gGlu)]mimylin designates a mimylin derivative, wherein mimylin in the N-terminal with a side chain comprising a C18diacid as the protracting moiety and gGlu as a linker.
[N-terminal(C18diacid-gGlu) 2P, 9V]mimylin designates a mimylin derivative, wherein a mimylin analogue comprising modification 2P and 9V, relative to the numbering of SEQ ID NO: 1 is derivatised in the N-terminal with a side chain comprising a C18diacid as the protracting moiety and gGlu as a linker.
The mimylin peptide may comprise one or more side chains on one or more of the amino acid residues. Such mimylin peptides may also be called mimylin derivatives or salmon calcitonin derivatives.
The term “derivative” as used herein means a chemically modified peptide, in which one or more side chains have been covalently attached to the peptide. The term “side chain” may also be referred to as a “substituent”. A derivative comprising such side chains will thus be “derivatised” peptide or “derivatised” analogue.
The term “mimylin compound” as used herein refers to the analogues and derivatives according to this invention which comprise a backbone which make reference to the mimylin backbone. Such as, but not limited to the compounds of Table 1 and 4.
In a particular embodiment, the side chain is capable of forming non-covalent aggregates with albumin and may thus also be referred to as “albumin binding moiety”, thereby promoting the circulation of the derivative with the blood stream, and also having the effect of protracting the time of action of the derivative, due to the fact that the aggregate of the mimylin-derivative and albumin is only slowly disintegrated to release the active pharmaceutical ingredient. Thus, the “substituent”, or “side chain”, as a whole is preferably referred to as an “albumin binding moiety”.
The term “albumin binding moiety” as used herein refers to any chemical group capable of non-covalent binding to albumin, i.e. has albumin binding affinity. In some embodiments the albumin binding moiety comprises an acyl group.
In another particular embodiment the side chain comprises a portion which is particularly relevant for the albumin binding and thereby the protraction, which portion may accordingly be referred to as a “protracting moiety” or “protractor”. The protracting moiety may be near, preferably at, the terminal (or distal, or free) end of the albumin binding moiety, relative to its point of attachment to the peptide.
In a still further particular embodiment the side chain comprises a portion between the protracting moiety and the point of attachment to the peptide, which portion may be referred to as a “linker”, “linker moiety”, “spacer”, or the like. The linker may be optional, and hence in that case the side chain may be identical to the protracting moiety.
The albumin binding moiety, the protracting moiety, or the linker may be covalently attached to a lysine residue of the mimylin peptide by acylation, i.e. via an amide bond formed between a carboxylic acid group thereof (of the albumin binding moiety, the protracting moiety, or the linker) and an amino group of the lysine residue or amino acid residue in the N-terminal. Additional or alternative conjugation chemistry includes alkylation, ester formation, or amide formation, or coupling to a cysteine residue, such as by maleimide or haloacetamide (such as bromo-/chloro-/iodo-) coupling.
In a preferred embodiment, an active ester of the albumin binding moiety, preferably comprising a protracting moiety and a linker, is covalently linked to an amino group of a lysine residue, preferably the epsilon amino group thereof, under formation of an amide bond, as explained above.
Unless otherwise stated, when reference is made to an acylation of a lysine residue or N-terminal amino acid, it is understood to be to the epsilon-amino group of said lysine residue or alpha-amino group of the N-terminal amino acid.
The term “epsilon amino group” or “ε-amino group”, used herein in relation to lysine, refers to the amino group at the 6 position, using the IUPAC standard numbering conventions. The term “alpha amino group” or “α-amino group” refers to the amino group at the 2 position, using the IUPAC standard numbering conventions. We refer to the following structure.
The term “linker” as used herein includes suitable side chains that can join a moiety, such as a chemical moiety, to the mimylin peptide, such as the mimylin peptide backbone. Thus, the linker and the chemical moiety become a side chain together. The moiety joined to the linker may be any suitable moiety. Examples include an albumin binding moiety.
A linker as used herein provides a bridge or link between an amino group on the mimylin peptide backbone and an acyl group on the moiety—such as an albumin binding moiety. The linker may be bound to, or near to, the N terminal amino acid residue. Preferably the linker is bound to the amino acid in position 1 of the mimylin analogue.
Another example of a linker is a combination of at least one amino acid and an amine.
The formula of another linker according to the present invention; OEG is shown below:
The linker can contribute to and/or enhance the binding effect of the moiety (for example the albumin binding moiety), e.g. a linker comprising γGlu can enhance the albumin binding effect of the mimylin peptide.
By using the term “γGlu” or “gGlu” or “gammaGlu” or “gamma-L-Glu” is meant an amino acid with the following structure and used interchangeably herein (also shown in
By using the term “γGlu-OEG” is meant a moiety with the following structure:
By using the term “γGlu-OEG-OEG” is meant moiety with the following structure:
The term “fatty acid” refers to aliphatic monocarboxylic acids having from 4 to 28 carbon atoms, it is preferably un-branched, and it may be saturated or unsaturated. In the present invention fatty acids comprising 10 to 16 amino acids are preferred.
The term “fatty diacid” refers to fatty acids as defined above but with an additional carboxylic acid group in the omega position. Thus, fatty diacids are dicarboxylic acids. In the present invention fatty acids comprising 14 to 20 amino acids are preferred.
The term “substituent” or “side chain” as used herein means any suitable moiety bonded, in particular covalently bonded, to an amino acid residue, in particular to any available position on an amino acid residue. Typically, the suitable moiety is a chemical moiety.
“Albumin binding affinity” may be determined by several methods known within the art. In one method the compound to be tested is radiolabeled with e.g. 125I or 3H and incubated with immobilized albumin (Kurtzhals et. al., Biochem. J., 312, 725-731 (1995)). The binding of the compound relative to a standard is calculated. In another method a related compound is radiolabeled and its binding to albumin immobilized on e.g. SPA beads is competed by a dilution series of the compound to be tested. The EC50 value for the competition is a measure of the affinity of the compound. In a third method, the receptor affinity or potency of a compound is tested at different concentrations of albumin, and the shift in relative affinity or potency of the compound as a function of albumin concentration reflects its affinity for albumin.
The term “disulfide bridge” can interchangeably be used for the term “disulfide bond”.
The mimylin peptides of the present invention exhibit good potency. The term “potency” is used to describe the effect of a given compound in assays where a sigmoidal relationship between log concentration and the effect of a compound has been established. Furthermore, the response should be variable from 0 to 100%. EC (effective concentration)50 can be used to describe the concentration of a given compound yielding a response of 50% in the assay, such as in the functional assay.
The mimylin peptides of the present invention exhibit good activity. The term “activity” refers to the ability to reduce appetite and/or increase satiety. The activity can be tested by the ability to reduce appetite as e.g. described in the Assay (I) herein.
The mimylin peptides of the present invention exhibit good physical stability. The term “physical stability” of a mimylin peptide according to the invention, or a formulation thereof refers to the tendency of the mimylin peptide not to form biologically inactive and/or insoluble aggregates as a result of exposure to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces. Physical stability of the aqueous mimylin peptide formulations may be evaluated by means of visual inspection, ThT fibrillation assay (sometimes referred to as a ThT fibrillogenesis assay) and/or turbidity measurements as described elsewhere herein. Visual inspection of the formulations is performed in a sharp focused light with a dark background. The turbidity of the formulation is characterised by a visual score ranking the degree of turbidity for instance on a scale from 0 to 3 (a formulation showing no turbidity corresponds to a visual score 0, and a formulation showing visual turbidity in daylight corresponds to visual score 3). A formulation is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight. Alternatively, the turbidity of the formulation can be evaluated by simple turbidity measurements well-known to the skilled person.
The mimylin peptides of the present invention exhibit good chemical stability. The term “chemical stability” of a mimylin peptide according to the invention or of a formulation thereof refers to no chemical covalent changes in the mimylin peptide structure hence avoiding the formation of chemical degradation products with potentially less potency and/or potentially increased immunogenic properties compared to the parent (native) mimylin peptide structure. Various chemical degradation products can be formed depending on the type and nature of the parent mimylin peptide and the environment to which the mimylin peptide is exposed. Chemical degradation can most probably not be completely avoided and increasing amounts of chemical degradation products is often seen during storage and use of peptide formulations as well-known by the person skilled in the art. Most peptides are prone to deamidation, a process in which the side chain amide group in glutaminyl or asparaginyl residues is hydrolysed to form a free carboxylic acid. Other degradations pathways involves formation of high molecular weight transformation products where two or more peptide molecules are covalently bound to each other through transamidation and/or disulfide interactions leading to formation of covalently bound dimer, oligomer and polymer degradation products (Stability of Protein Pharmaceuticals, Ahern. T. J. & Manning M. C., Plenum Press, New York 1992). Oxidation (of for instance methionine residues) can be mentioned as another variant of chemical degradation. The chemical stability of the mimylin peptide formulation can be evaluated by measuring the amount of the chemical degradation products at various time-points after exposure to different environmental conditions (the formation of degradation products can often be accelerated by for instance increasing temperature). The amount of each individual degradation product is often determined by separation of the degradation products depending on molecule size and/or charge using various chromatography techniques (e.g. SEC-HPLC and/or RP-HPLC).
While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended aspects are intended to cover all such modifications and changes as fall within the true spirit of the invention.
Non-limiting examples of GLP-1 compound include a natural GLP-1, a GLP-1 analogue or a GLP-1 derivative. In its broadest sense, the term “natural GLP-1” refers to a naturally occurring molecule of the glucagon family of peptides or of the family of exendins. The glucagon family of peptides are encoded by the pre-proglucagon gene and encompasses three small peptides with a high degree of homology, i.e. glucagon (1-29), GLP-1 (1-37) and GLP-2 (1-33). The term “natural GLP-1” also refers to the human GLP-1 (7-37), the sequence of which is disclosed as SEQ ID NO: 1 in WO 2006097537 and included herein by reference, and to the human GLP-1 (7-36)NH2. Exendins are peptides expressed in lizards and like GLP-1, are insulinotropic. Examples of naturally occurring exendins are exendin-3 and exendin-4.
In a particular embodiment, the term “natural GLP-1” refers to glucagon (1-29), GLP-1 (1-37) and GLP-2 (1-33), the human GLP-1 (7-37)), the human GLP-1 (7-36)NH2, exendin-3 and exendin-4.
In a particular embodiment, the term “GLP-1 compound” does not include the human GLP-1 (7-36)NH2. In a particular embodiment, the term “GLP-1 compound” does not include the human GLP-1 (7-37).
In a particular embodiment, the term “GLP-1 compound” does not include glucagon.
In a particular embodiment, the term “GLP-1 compound” does not include the human GLP-1 (7-36)NH2 and glucagon or does not include human GLP-1 (7-36)NH2, human GLP-1 (7-37) and glucagon.
In a more particular embodiment, the term “natural GLP-1” only refers to the human GLP-1 (7-37).
In its broadest sense, the term “GLP-1 analogue” or “analogue of GLP-1” as used herein refers to an analogue of a natural GLP-1. It does not include a natural GLP-1 as such as defined herein. In particular, the term “GLP-1 analogue” does not include glucagon (1-29), GLP-1 (1-37) and GLP-2 (1-33), the human GLP-1 (7-37)), the human GLP-1 (7-36)NH2, exendin-3 and exendin-4.
In a particular embodiment, the term “GLP-1 analogue” or “analogue of GLP-1” as used herein refers to an analogue of human GLP-1 (7-37) or GLP-1 (7-36)NH2. Non-limiting examples of GLP-1 analogues comprise exenatide and taspoglutide.
In a particular embodiment, the “GLP-1 analogues” comprise analogues with a maximum of 17 amino acid modifications (i.e. up to 17 amino acids have been modified in total, where the changes can be amino acid substitutions, additions and/or deletions) compared to a natural GLP-1 of reference or, in particular, compared to human GLP-1-(7-36)NH2 or GLP-1 (7-37).
All amino acids for which the optical isomer is not stated is to be understood to mean the L-isomer.
In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 17 amino acids which have been modified (substituted, deleted, added or any combination thereof) relative to a natural GLP-1 of reference or, in particular, relative to human GLP-1-(7-36)NH2 or GLP-1 (7-37). In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 15 amino acids which have been modified. In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 10 amino acids which have been modified. In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 8 amino acids which have been modified. In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 7 amino acids which have been modified. In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 6 amino acids which have been modified. In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 5 amino acids which have been modified. In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 4 amino acids which have been modified. In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 3 amino acids which have been modified. In embodiments of the invention a GLP-1 compound or GLP-1 analogue comprises a maximum of 2 amino acids which have been modified. In embodiments of the invention 1 amino acid has been modified relative to a natural GLP-1 of reference or, in particular, relative to human GLP-1-(7-36)NH2 or GLP-1 (7-37). In a particular embodiment, the amino acid modifications of this paragraph are relative to human GLP-1 (7-37).
In a particular embodiment, the GLP-1 analogues comprise a substitution of the amino acid residue in position 34 from Lys to Arg, i.e. Arg34, compared to GLP-1 (7-37) or GLP-1-(7-36)NH2. In a particular embodiment, the GLP-1 analogues have a substitution of the amino acid residue in position 8 from Ala to Aib (alpha-amino-iso-butyric acid), i.e. Aib8. In a particular embodiment, the GLP-1 analogues have the Arg34 substitution, the Aib8 substitution, or both the Arg34 and Aib8 substitutions, and possibly one more amino acid modification compared to GLP-1 (7-37) or GLP-1-(7-36)NH2. In a particular embodiment, the amino acid modifications of this paragraph are relative to human GLP-1 (7-37).
In its broadest sense, the term “GLP-1 derivative” or “derivative of GLP-1” as used herein refers to a derivative of a parent peptide selected from a natural GLP-1 or an analogue thereof. It does not include a natural GLP-1 as such as defined herein. In particular, the term “GLP-1 derivative” does not include glucagon (1-29), GLP-1 (1-37) and GLP-2 (1-33), the human GLP-1 (7-37)), the human GLP-1 (7-36)NH2, exendin-3 and exendin-4.
In a particular embodiment, the term “GLP-1 derivative” or “derivative of GLP-1” refers to a derivative of a parent peptide selected from human GLP-1(7-37) or GLP-1(7-36)NH2 or an analogue thereof.
In a particular embodiment, the term “GLP-1 derivative” or “derivative of GLP-1” as used herein refers to a derivative of a parent peptide selected from a GLP-1 analogue, where said analogue comprises a maximum of 17 amino acid modifications compared to a natural GLP-1 of reference or, in particular, compared to human GLP-1-(7-36)NH2 or GLP-1(7-37), or, in particular, compared to human GLP-1(7-37). In one embodiment, the “GLP-1 derivative”, in particular when defined in comparison to GLP-1(7-37), does not include GLP-1(7-36)NH2.
Typical modifications are amides, carbohydrates, alkyl groups, acyl groups, esters, polyethylene glycol (PEG) groups, sialylation groups, glycosylation groups and the like of a parent peptide. In one embodiment, the parent peptide is a GLP-1 analogue as defined above.
In particular embodiments, the side chain has at least 10 carbon atoms, or at least 15, 20, 25, 30, 35, or at least 40 carbon atoms. In further particular embodiments, the side chain may further include at least 5 hetero atoms, in particular 0 and N, for example at least 7, 9, 10, 12, 15, 17, or at least 20 hetero atoms, such as at least 1, 2, or 3 N-atoms, and/or at least 3, 6, 9, 12, or 15 O-atoms.
In one embodiment, the term “GLP-1 derivative” refers to acylated GLP-1 parent peptide. In a particular embodiment, the term “GLP-1 derivative” refers to acylated GLP-1 parent peptide where the parent peptide is selected from a GLP-1 analogue comprising a maximum of 17 amino acid modifications compared to a natural GLP-1 of reference or, in particular, compared to human GLP-1-(7-36)NH2 or GLP-1(7-37).
The side chain may be covalently attached to a lysine residue of the GLP-1 parent peptide by acylation. Additional or alternative conjugation chemistry includes alkylation, ester formation, or amide formation, or coupling to a cysteine residue, such as by maleimide or haloacetamide (such as bromo-/fluoro-/iodo-) coupling.
For the preparation, an active ester of the side chain is covalently linked to an amino group of a lysine residue, preferably the epsilon amino group thereof, under formation of an amide bond (this process being referred to as acylation).
Preferred side chains include, for example, fatty acids and fatty diacids. The term fatty acid refers to aliphatic monocarboxylic acids having from 4 to 28 carbon atoms. The fatty acid may be branched or unbranched. The fatty acid is preferably even numbered. The fatty acid may be saturated or unsaturated. The term fatty diacid refers to fatty acids as defined above but with an additional carboxylic acid group in the omega position. Thus, fatty diacids are dicarboxylic acids.
In a particular embodiment, the side chain(s) is a fatty acid having 10 to 20 carbon atoms, and preferably 14 to 20 or 16 to 18 carbon atoms, optionally with a spacer.
In a particular embodiment, the side chain(s) is a fatty acid of formula Chem. 1: HOOC(CH2)mCO, wherein m is an integer from 8 to 18, optionally with a linker. In a particular embodiment, m is an integer from 12 to 18 or from 14 to 16.
In a particular embodiment, the side chain(s) is selected from the group consisting of HOOC(CH2)14CO—, HOOC(CH2)16CO—, HOOC(CH2)22CO—, CH3(CH2)14CO—, CH3(CH2)16CO— and CH3(CH2)18CO—.
In one embodiment, the term “GLP-1 derivative” comprises or refers to monoacylated GLP-1 parent peptide, i.e. a GLP-1 parent peptide comprising only one acylation as defined above.
In a particular embodiment, the side chain is a fatty acid or a fatty diacid of which an acid group forms an amide bond with the epsilon amino group of a lysine residue in the GLP-1 compound, preferably via a spacer. In one embodiment, said lysine residue is Lys26, especially when the parent peptide is human GLP-1(7-37), GLP-1(7-36)NH2 or a GLP-1 analogue.
In a particular embodiment, the side chain is attached to the parent peptide by means of a linker. In a particular embodiment, the linker comprises a γ-glutamic acid (γ-Glu) and/or 1, 2 or 3 OEG molecules. In γGlu the gamma carboxy group of the amino acid glutamic acid is used for connection to another linker element, or to the epsilon-amino group of lysine. An OEG molecule is also named a di-radical of 8-amino-3,6-dioxaoctanic acid, and/or it may be represented by the formula Chem. 2: —NH—(CH2)2-O—(CH2)2-O—CH2-CO—.
The linker may include one or more γGlu, and/or one or more OEG. More in particular, the γGlu and OEG linker elements may, independently, be used p times where p is zero or an integer in the range of 1-3. Examples of preferred linkers are γGlu, γGlu-2×OEG, and γGlu-3×OEG where in all cases the alpha-amino group of Glu forms an amide bond with the carboxy group of the protracting moiety.
In a particular embodiment, the GLP-1 derivative is a derivative of a GLP-1 analogue which comprises the Arg34 substitution or the Arg34 and the Aib8 substitutions compared to human GLP-1(7-37), GLP-1(7-36)NH2 and which comprises a side chain attached to Lys26. In a particular embodiment said side chain is a fatty acid as defined above, especially a fatty acid of formula Chem.1, with m being an integer from 8 to 18, optionally with a linker being γGlu.
In one embodiment, the GLP-1 derivative is as defined in the patent applications WO 98/08871 and WO 06/097537, entirely included herein by reference. Non-limiting examples of monoacylated GLP-1 derivatives can be found in those applications.
Non-limiting examples of GLP-1 derivatives also include:
In a particular embodiment, the GLP-1 derivative is liraglutide or semaglutide. The chemically modified derivatives of natural GLP-1 can be prepared for example as described in U.S. Pat. No. 6,451,762 or in Knudsen et. al. (2000) J Med Chem 43, 1664-1669.
When using terms such as “about” and “approximately” in relation to numerical values the skilled person should immediately recognise that any effect or result, which may be associated with the given values can be obtained within a certain tolerance from the particular values. The term “about” as used herein thus means in reasonable vicinity of the stated numerical value, such as plus or minus 10%.
Some of the abbreviations used in the Examples are as follows:
The production of peptides like mimylin is well known in the art.
The mimylin peptide/mimylin analogue of the invention may for instance be produced by classical peptide synthesis, e.g., solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well established techniques, see, e.g., Greene and Wuts, “Protective Groups in Organic Synthesis”, John Wiley & Sons, 1999, Florencio Zaragoza Dorwald, “Organic Synthesis on solid Phase”, Wiley-VCH Verlag GmbH, 2000, and “Fmoc Solid Phase Peptide Synthesis”, Edited by W. C. Chan and P. D. White, Oxford University Press, 2000.
Also, or alternatively, they may be produced by recombinant methods, viz. by culturing a host cell containing a DNA sequence encoding the analogue and capable of expressing the peptide in a suitable nutrient medium under conditions permitting the expression of the peptide. Non-limiting examples of host cells suitable for expression of these peptides are: Escherichia coli, Saccharomyces cerevisiae, as well as mammalian BHK or CHO cell lines.
Those peptides, analogues or derivatives of the invention which include non-natural amino acids and/or a covalently attached N-terminal mono- or dipeptide mimetic may e.g. be produced as described in the experimental part. Or see e.g., Hodgson et al: “The synthesis of peptides and proteins containing non-natural amino acids”, Chemical Society Reviews, vol. 33, no. 7 (2004), p. 422-430; and WO 2009/083549 A1 entitled “Semi-recombinant preparation of GLP-1 analogues”.
The mimylin peptide sequences were prepared according to the below-mentioned mimylin peptide synthesis and the compounds as presented in the Tables (e.g. Table 1 or Table 2) were prepared according to the below-mentioned synthesis.
One method of mimylin peptide synthesis was by Fmoc chemistry on a microwave-based Liberty peptide synthesizer (CEM Corp., North Carolina). The resin was Tentagel S RAM with a loading of about 0.25 mmol/g or PAL-ChemMatrix with a loading of about 0.43 mmol/g or PAL AM matrix with a loading of 0.5-0.75 mmol/g. The coupling chemistry was DIC/HOAt or DIC/Oxyma in NMP or DMF using amino acid solutions of 0.3 M and a molar excess of 6-8 fold. Coupling conditions was 5 minutes at up to 70° C. Deprotection was with 10% piperidine in NMP at up to 70° C. The protected amino acids used were standard Fmoc-amino acids (supplied from e.g. Anaspec or Novabiochem or Protein Technologies).
Another method of mimylin peptide synthesis was by Fmoc chemistry on a Prelude peptide synthesizer (Protein Technologies, Arizona). The resin was Tentagel S RAM with a loading of about 0.25 mmol/g or PAL-ChemMatrix with a loading of about 0.43 mmol/g or PAL AM with a loading of 0.5-0.75 mmol/g. The coupling chemistry was DIC/HOAt or DIC/Oxyma in NMP or DMF using amino acid solutions of 0.3 M and a molar excess of 6-8 fold. Coupling conditions was single or double couplings for 1 or 2 hours at room temperature. Deprotection was with 20% piperidine in NMP. The protected amino acids used were standard Fmoc-amino acids (supplied from e.g. Anaspec or Novabiochem or Protein Technologies).
N-terminal attachment of fatty acids, linkers etc. were usually performed by including the relevant building blocks in the standard peptide synthesis.
When a chemical modification of a lysine side chain was desired, the lysine was incorporated as Lys(Mtt) and the N-terminal amino acid was either incorporated into the sequence as a Boc-amino acid or, if the N-terminal amino acid was incorporated as an Fmoc-amino acid, the Fmoc group was removed and the N-terminal was protected by treatment with 6 equivalents of Boc-carbonate and 6 equivalents of DIPEA in NMP for 30 minutes. The resin was washed with NMP and DCM and the Mtt group was removed by suspending the resin in neat hexafluoroisopropanol or HFIP/DCM 3:1 for 20 minutes followed by washing with DCM and NMP. The chemical modification of the lysine was performed by adding one or more of the building blocks listed below by the same methods as used for the mimylin peptide synthesis, i.e. by one or more automated steps on the Liberty or by one or more manual coupling steps at room temperature. After synthesis the resin was washed with DCM and dried, and the mimylin peptide was cleaved from the resin by a 2 hour treatment with TFA/TIPS/water (92.5/5/2.5 or 95/2.5/2.5) followed by precipitation with 4 volumes of diethylether, further washing with diethylether and drying.
Purification: The crude mimylin peptide was purified by semipreparative HPLC on a 20 mm×250 mm column packed with either 5 um or 7 um C-18 silica. Mimylin peptide solutions were pumped onto the HPLC column and precipitated mimylin peptides were dissolved in 5 ml 50% acetic acid H2O and diluted to 20 ml with H2O and injected on the column which then was eluted with a gradient of 40-60% CH3CN in 0.1% TFA 10 ml/min during 50 min at 40° C. The mimylin peptide containing fractions were collected. The purified mimylin peptide was lyophilized after dilution of the eluate with water.
For analysis of HPLC-fractions and final product RP-HPLC analysis was performed using UV detection at 214 nm and e.g. a Vydac 218TP54 4.6 mm×250 mm 5 um C-18 silica column (The Separations Group, Hesperia, USA) and eluted at e.g. 1 ml/min at 42° C. Most often one of four different elution conditions was used:
A1: Equilibration of the column with a buffer consisting of 0.1M (NH4)2SO4, which was adjusted to pH 2.5 with concentrated H2SO4 and elution by a gradient of 0% to 60% CH3CN in the same buffer during 50 min.
B1: Equilibration of the column with 0.1% TFA/H2O and elution by a gradient of 0% CH3CN/0.1% TFA/H2O to 60% CH3CN/0.1% TFA/H2O during 50 min.
B6: Equilibration of the column with 0.1% TFA/H2O and elution by a gradient of 0% CH3CN/0.1% TFA/H2O to 90% CH3CN/0.1% TFA/H2O during 50 min.
Alternatively the RP-HPLC analysis was performed using UV detection at 214 nm and a Symmetry 300, 3.6 mm×150 mm, 3.5 um C-18 silica column (Waters) which was eluted at 1 ml/min at 42° C.
B4: Equilibration of the column with 0.05% TFA/H2O and elution by a gradient of 5% CH3CN/0.05% TFA/H2O to 95% CH3CN/0.05% TFA/H2O during 15 min.
The identity of the mimylin peptide was confirmed by MALDI-MS on a Bruker Microflex.
400 mg PAL AM resin (0.61 mmol/g) was swollen in DCM/NMP and synthesis was performed on a Prelude peptide synthesizer using 1 hour couplings in DMF as described above. After cleavage with TFA cleavage cocktail, the peptide was precipitated with ether and dried yielding 800 mg crude mimylin with a purity of about 50%. HPLC purification (as described above) gave about 200 mg mimylin with a purity of >90%
600 mg PAL ChemMatrix resin (0.43 mmol/g) was swollen in DCM/NMP and synthesis was performed on a Liberty peptide synthesizer using 5 min couplings in NMP at 70° C. as described above. As the last step of the synthesis C18-diacid-mono-t-butylester was coupled under the same conditions. After cleavage, the peptide was precipitated with ether and dried yielding 700 mg crude [N-terminal(C18 diacid)]mimylin with a purity of about 55%. HPLC purification gave about 150 mg [N-terminal(C18 diacid)]mimylin with a purity of >90%
Mimylin is synthesized and purified as described above, dissolved in water or a suitable mixture of water and an organic solvent such as e.g. NMP, DMF, DMSO, or acetonitrile. A solution of activated C18-diacid, e.g. C18-diacid-succinimidyl ester is added and the resulting solution of Example 2 is purified.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.
This invention includes all modifications and equivalents of the subject matter recited in the aspects appended hereto as permitted by applicable law.
Sprague Dawley (SD) rats from Taconic Europe, Denmark are used for the experiments. The rats have a body weight 200-250 g at the start of experiment. The rats arrive at least 10-14 days before start of experiment to allow acclimatisation to experimental settings. During this period the animals are handled at least 2 times. After arrival rats are housed individually for one week in a reversed light/dark phase (meaning that lights are off during daytime and on during nighttime) for two weeks. Since rats are normally active and eat their major part of their daily food intake during the dark period, rats are dosed in the morning right before lights are turned off. This set-up results in the lowest data variation and highest test sensitivity. The experiment is conducted in the rats' home cages and rats have free access to food and water throughout the acclimatization period and the experiment period. Each dose of derivative is tested in a group of 5-8 rats. A vehicle group of 6-8 rats is included in each set of testing. Rats are dosed once according to body weight with a 0.01-3 mg/kg solution administered intraperitoneally (ip), orally (po) or subcutaneously (sc). The time of dosing is recorded for each group.
After dosing, the rats are returned to their home cages, where they then have access to food and water. The food consumption is recorded individually continuously by on-line registration or manually every hour for 7 hours, and then after 24 h and sometimes 48 h. At the end of the experimental session, the animals are euthanised. The individual data are recorded in Microsoft excel sheets. Outliers are excluded after applying the Grubbs statistical evaluation test for outliers, and the result is presented graphically using the GraphPad Prism program.
Activation of calcitonin and amylin (co-expression of calcitonin receptor and receptor activity modifying proteins (RAMP)) receptors lead to increased intracellular concentrations of cAMP. Consequently, transcription is activated by promoters containing multiple copies of the cAMP response element (CRE). It is thus possible to measure amylin activity by the use of a CRE luciferase reporter gene introduced into BHK cells also expressing calcitonin or amylin receptors.
2. Construction of Calcitonin (a)—and Amylin 3(a)—Receptor/CRE-Luc Cell Line.
A BHK570 cell line was stably transfected with the human calcitonin receptor and a CRE-responsive luciferase reporter gene. The cell line was further transfected with RAMP-3, using standard methods. This turns the calcitonin receptor into an amylin 3(a) receptor. Methotrexate, Neomycin, and Hygromycin are selection markers for luciferase, the calcitonin receptor, and RAMP-3, respectively.
To perform activity assays, BHK calcitonin (a) receptor- or amylin 3(a)-receptor/CRE-luc cells were seeded in white 96 well culture plates at a density of about 20.000 cells/well. The cells were in 100 μl growth medium (DMEM with 10% FBS, 1% Pen/Strep, 1 mM Na-pyruvate, 250 nM Methotrexate, 500 μg/ml Neomycin, and 400 μg/ml Hygromycin). After incubation overnight at 37° C. and 5% CO2, the growth medium was replaced by 50 μl/well assay medium (DMEM (without phenol red), Glutamax™, 10% FBS, and 10 mM Hepes, pH 7.4). Further, 50 μl/well of standard or sample in assay buffer were added.
After 3 hours incubation at 37° C. and 5% CO2, the assay medium with standard or sample were removed and replaced by 100 μl/well PBS. Further, 100 μl/well LucLite™ was added. The plates were sealed and incubated at room temperature for 30 minutes. Finally, luminescence was tested on a TopCounter (Packard) in SPC (single photon counting) mode.
Assay(II)b—Human Calcitonin and Amylin Receptor Assay without Albumin
Activation of calcitonin and amylin (co-expression of calcitonin receptor and receptor activity modifying proteins (RAMP)) receptors lead to increased intracellular concentrations of cAMP. Consequently, transcription is activated by promoters containing multiple copies of the cAMP response element (CRE). It is thus possible to measure amylin activity by the use of a CRE luciferase reporter gene introduced into BHK cells also expressing calcitonin or amylin receptors.
2. Construction of Calcitonin (a)—and Amylin 3(a)—Receptor/CRE-Luc Cell Line.
A BHK570 cell line was stably transfected with the human calcitonin receptor and a CRE-responsive luciferase reporter gene (Hollex-1 cell line, obtained from ZymoGenetics described in U.S. Pat. No. 5,622,839). The cell line was further transfected with RAMP-3, using standard methods. This turns the calcitonin receptor into an amylin 3(a) receptor. Methotrexate, Neomycin, and Hygromycin are selection markers for luciferase, the calcitonin receptor, and RAMP-3, respectively. To prepare the batches of frozen cells used in the luciferase assay described in the section below, the cells were cultured in growth medium (DMEM with 10% FBS, 1% Pen/Strep and 1 mM Napyruvate). Methotrexate (250 nM) and Neomycin (500 μg/ml) were used as selection markers for the expression of the luciferase reporter and the calcitonin receptor, respectively. Cells at approximately 80-90% confluence were washed with PBS and loosened from the plates with Versene. After centrifugation (2 min, 1300 rpm, in a Centrion Scientific centriuge C2 series with a BRK 5510 rotor head), the cell pellet was dissolved in 10% DMSO, 30% FBS and 60% growth medium and frozen (−80° C.) until utilization.
The day before the experiment, BHK calcitonin (a) receptor- or amylin 3(a)-receptor/CRE-luc cells were thawed, washed twice, and seeded in 40 μl growth medium on white 384 well culture plates (4.000 cells/well). On the assay day, the cells were washed 3 times in assay media (Dulbecco media W/o phenol red, 500 ml (Gibco, 11880-028); 0.1% ovalbumin; 10 mM Hepes pH 7.4; 1× Glutamin; 1% Pen/Strep). Then, 30 μl/well of sample diluted in assay buffer was added. After 3 hours of incubation at 37° C. and 5% CO2, the reaction was terminated by adding 30 μl/well SteadyLite Plus™. The plates were shaken at 300 rpm for 5 min at RT. Then, the plates were sealed and incubated at room temperature for 30 minutes. Finally, luminescence was tested on a TopCounter (Packard) in SPC (single photon counting) mode.
EC50 values were calculated in GraphPad Prism using a nonlinear regression with hillslope=1.
Additional Comment Regarding Use of Data Retrieved Via this Method
This assay provides confirmation of biologic activity and confirms that all mimylin peptides or derivatives as described herein are amylin and calcitonin receptor agonists. Due to the presence of HSA it should be noted that mimylin derivatives with different protracting moieties should not be compared relative regarding their EC50 value, because different side chains bind to HSA with different affinities and thus influence the EC50 and thus shift the EC50 towards higher values when the protracting moiety binds more efficiently to HSA. For the same reasons, measurements made in Assay IIa should not be compared in Assay IIb.
cAMP Assay Outline
Activation of calcitonin and amylin (co-expression of calcitonin receptor and receptor activity modifying proteins (RAMP)) receptors lead to increased intracellular concentrations of cAMP. In order to quantify the cAMP levels in transiently transfected cells the Adenylyl Cyclase Activation FlashPlate® Assay from Perkin Elmer was used. The basic principle of the FlashPlate® Assay is a competition between radioactive and non-radioactive cAMP generated by the cells for a fixed number of binding sites.
Construction of Rat Calcitonin(a)—and Rat Amylin 3(a)-Receptor Cells.
BHK tk'ts 13 cells were transiently transfected with either rat calcitonin (a) receptor or amylin 3 (a) receptor (rat calcitonin(a) receptor+ rat RAMP3) using FuGENE® 6 (Roche), according to the manufacturers recommendations.
cAMP Assay
24 hours after transient transfection the cells (rat calcitonin(a)—or rat amylin 3(a)—receptor cells) were added (100,000 cells/well) to the 96 well FlashPlates® with samples or standard in FlashPlate stimulation buffer with IBMX and incubated for 30 min. Detection mix was created according to manufacturer's protocol and scintillation tested after 3 h of incubation on TopCounter™ (Packard).
Low physical stability of a mimylin peptide may lead to amyloid fibril formation, which is observed as well-ordered, thread-like macromolecular structures in the sample eventually resulting in gel formation. This has traditionally been tested by visual inspection of the sample. However, that kind of measurement is very subjective and depending on the observer. Therefore, the application of a small molecule indicator probe is much more advantageous. Thioflavin T (ThT) is such a probe and has a distinct fluorescence signature when binding to fibrils [Naiki et al. (1989) Anal. Biochem. 177, 244-249; LeVine (1999) Methods. Enzymol. 09, 274-284].
The time course for fibril formation can be described by a sigmoidal curve with the following expression [Nielsen et al. (2001) Biochemistry 40, 6036-6046]:
Here, F is the ThT fluorescence at the time t. The constant t0 is the time needed to reach 50% of maximum fluorescence. The two important parameters describing fibril formation are the lag-time calculated by t0−2τ and the apparent rate constant kapp=1/τ.
Formation of a partially folded intermediate of the mimylin peptide is suggested as a general initiating mechanism for fibrillation. Few of those intermediates nucleate to form a template onto which further intermediates may assembly and the fibrillation proceeds. The lag-time corresponds to the interval in which the critical mass of nucleus is built up and the apparent rate constant is the rate with which the fibril itself is formed.
Samples were prepared freshly before each assay. Each sample composition is described in each example. The pH of the sample was adjusted to the desired value using appropriate amounts of concentrated NaOH and HClO4 or HCl. Thioflavin T was added to the samples from a stock solution in H2O to a final concentration of 1 μM. Sample aliquots of 200 μl were placed in a 96 well microtiter plate (Packard OptiPlate™-96, white polystyrene). Usually, four or eight replica of each sample (corresponding to one test condition) were placed in one column of wells. The plate was sealed with Scotch Pad (Qiagen).
Incubation at given temperature, shaking and measurement of the ThT fluorescence emission were done in a Fluoroskan Ascent FL fluorescence plate reader or Varioskan plate reader (Thermo Labsystems). The temperature was adjusted to 37° C. The orbital shaking was adjusted to 960 rpm with an amplitude of 1 mm in all the presented data. Fluorescence measurement was done using excitation through a 444 nm filter and measurement of emission through a 485 nm filter.
Each run was initiated by incubating the plate at the assay temperature for 10 min. The plate was tested every 20 minutes for a desired period of time. Between each measurement, the plate was shaken and heated as described.
The measurement points were saved in Microsoft Excel format for further processing and curve drawing and fitting was performed using GraphPad Prism. The background emission from ThT in the absence of fibrils was negligible. The data points are typically a mean of four or eight samples and shown with standard deviation error bars. Only data obtained in the same experiment (i.e. samples on the same plate) are presented in the same graph ensuring a relative measure of fibrillation between experiments.
The data set may be fitted to Eq. (1). However, since full sigmodial curves in this case are not always achieved during the measurement time, the degree of fibrillation is expressed as ThT fluorescence tabulated as the mean of the samples and shown with the standard deviation at various time points.
The mimylin peptide concentration in each of the tested formulations was tested both before application in the ThT fibrillation assay (“Initial”) and after completion of the ThT fibrillation (“After ThT assay”). Concentrations were determined by reverse HPLC methods using a pramlintide standard as a reference. Before measurement after completion 150 μl was collected from each of the replica and transferred to an Eppendorf tube. These were centrifuged at 30000 G for 40 mins. The supernatants were filtered through a 0.22 μm filter before application on the HPLC system.
Sample preparation, incubation and fluorescence measurements were done according to the principles described under ASSAY (III).
Fluorescence measurements for each microtiter plate well were plotted against time and the lag-time (time until an increase in ThT fluorescence was observed) was estimated based on the intercept between the linear initial lag-phase and the first part of the subsequent exponential growth phase.
Done according to the principles described above in Assay III; however, ASSAY (XII) was used for quantification of peptide concentration before and after incubation.
RP-UPLC was conducted using an Acquity UPLC BEH C18 1.7 μm (2.1×30 mm) column (Eluent A: 0.1 v/v % TFA in water; Eluent B: 0.1 v/v % TFA in acetonitrile) with gradient elution (0 min: 95% A; 2 min: 20% A; 2.3 min: 20% A; 2.4 min: 95% A) in a flow rate of 0.9 ml/min and a column temperature of 30° C. UV-detection at 215 nm was used to assess the total peptide recovery (on an individual basis if separated) whereas detection at 280 nm was used to determine the recovery of the GLP-1 component (no UV-280 nm absorption from the mimylin component).
The mimylin peptide was dissolved in water at ˜500 nmol/ml and mixed 1:1 with a series of buffers (100 mM glycylglycine pH 3.0, 100 mM glycylglycine pH 4.0, 100 mM glycylglycine pH 5.0, 100 mM bistrispropane pH 6.0, 100 mM bistrispropane pH 6.5, 100 mM bistrispropane pH 7.0, 100 mM bistrispropane pH 7.5, 100 mM bistrispropane pH 8.0). After 18 hours at room temperature the samples were centrifuged and the mimylin peptide concentration determined by UPLC.
The binding assay was performed using scintillation proximity assay (SPA) beads (RPNQ0001) from PerkinElmer and cell membranes from the Amylin 3(a)/CRE-luc cells (as described in Assay (II)) were used. Membranes were prepared in the following way; the cells were rinsed with PBS and incubated with Versene for approximately 5 min before harvesting. The cells were flushed with PBS and the cell-suspension was centrifuged for 5 min at 1000 rpm. Cells were homogenized (ultrathurrax) in a buffer containing 20 mM Na-HEPES and 10 mM EDTA (pH 7.4) and centrifuged at 20.000 rpm for 15 min. The resulting pellet was resuspended, homogenized and centrifuged (20.000 rpm, 15 min) in a buffer containing 20 mM Na-HEPES and 0.1 mM EDTA (pH 7.4, buffer 2). The resulting pellet was resuspended in buffer 2 and protein concentration was tested (BCA protein Assay, Pierce). The homogenate was kept cold during the whole procedure. The membranes were kept at −80° C. until use. The assay was performed in a 384 well Optiplate (PerkinElmer) in a total volume of 40 ul. Membranes were mixed with SPA beads. Final concentration of membranes 35 ng/μL final and SPA beads was 0.05 mg/well. Test-compounds were dissolved in DMSO and further diluted in assay buffer (50 mM Hepes, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 0.1% OA and 0.02% Tween20). Radioligand 125I-rat amylin (NEX448 PerkinElmer) was dissolved in assay buffer and added to the Optiplate at a final concentration of 50 pM/well (approx. 20.000 cpm/10 ul). The final mixture was incubated with shaking at 400 rpm for 120 min at 25° C. prior to centrifugation (1500 rpm, 10 min). Samples were analyzed on TopCounter™ (Packard). The IC50 was calculated using (one site binding competition analysis) GraphPad Prism5 as a measure of receptor affinity.
The binding assay was performed using a BHK tk'ts 13 cell line was stably transfected with the human calcitonin receptor, the human RAMP3 and a CRE-responsive luciferase reporter gene.
The day before the assay the cells were Seeded into Poly-D-Lysin coated 384W Opaque White, BD BioCoat plates (10000 cells/well) and Incubated overnight at 37° C., 5% CO2, 95% humidity. Then, the cells were washed in HBSS (4° C.), and incubated overnight at 4° C. in a binding buffer containing test compounds, 50 pM [125I]-rat amylin, Dulbecco media w/o phenol red, 500 ml, 0.1% ovalbumin (5 ml 10% ovalbumin), 10 mM Hepes (5 ml 1M) 1× Glutamin (5 ml 100×) 1% P/S (5 ml 100%) Complete (1 tablet/50 ml)
0.1% Pluronic F68®. The morning after, the plates were washed three times in HBSS (4° C.), and lyzed in Lysis buffer (0.1 M NaOH (VWR #1.09136.1000), 1% SDS. Then MicroScint40 was addes and the plated were shaken at 500 rpm for a short period. Then the plate was incubated at room temperature in the dark for 1 hour and Read on a TopCounter. The IC50 was calculated using (one site binding competition analysis) GraphPad Prism5 as a measure of receptor affinity.
The assay was performed as described above (Assay (V)—Determination of binding to the human amylin receptor) with the exception that we used membranes prepared from BHK tk'ts 13 cells that were transiently transfected with the rat calcitonin receptor rat RAMP 3 at an equimolar ratio (1:2). The BHK tk'ts 13 cells were transiently transfected with rat calcitonin receptor using FuGENE® 6 (Roche), according to the manufacturer's recommendations. Cells were grown in DMEM with 10% FBS and 1% Pen/Strep. Approximately 48 hours after transfection, the cells were harvested and membranes were prepared.
The binding assay was performed using scintillation proximity assay (SPA) beads (RPNQ0001) from PerkinElmer® and cell membranes prepared from a BHK tk'ts 13 cell line was stably transfected with the human calcitonin receptor and a CRE-responsive luciferase reporter gene. Membranes were prepared in the following way; the cells were rinsed with PBS and incubated with Versene for approximately 5 min before harvesting. The cells were flushed with PBS and the cell-suspension was centrifuged for 5 min at 1000 rpm. Cells were homogenized in a buffer containing 20 mM Na-HEPES and 10 mM EDTA (pH 7.4) and centrifuged at 20.000 rpm for 15 min. The resulting pellet was resuspended, homogenized and centrifuged (20.000 rpm, 15 min) in a buffer containing 20 mM Na-HEPES and 0.1 mM
EDTA (pH 7.4, buffer 2). The resulting pellet was resuspended in buffer 2 and protein concentration was tested (BCA protein Assay, Pierce). The homogenate was kept cold during the whole procedure. The membranes were kept at −80° C. until use. Assay was performed in a 384 well Optiplate (PerkinElmer®) in a total volume of 40 ul. Membranes were mixed with SPA beads. Final concentration of membranes 35 ng/μL final and Final concentration of SPA beads was 0.05 mg/well. Test-compounds were dissolved in DMSO and further diluted in assay buffer (50 mM Hepes, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 0.1% OA and 0.02% Tween20). Radioligand 125I-Calcitonin was dissolved in assay buffer and added to the Optiplate at a final concentration of 75 pM/well (approx. 30.000cpm/10 ul). The final mixture was incubated for 120 min with shaking at 400 rpm at 25° C. prior to centrifugation (1500 rpm, 10 min). Samples were analyzed on TopCounter™ (Packard). The IC50 was calculated using (one site binding competition analysis) GraphPad Prism5 as a measure of receptor affinity.
The binding assay was performed using a BHK tk'ts 13 cell line was stably transfected with the human calcitonin receptor, and a CRE-responsive luciferase reporter gene.
The day before the assay the cells were Seeded into Poly-D-Lysin coated 384W Opaque White, BD BioCoat plates (10000 cells/well) and Incubated overnight at 37° C., 5% CO2, 95% humidity. Then, the cells were washed in HBSS (4° C.), and incubated overnight at 4° C. in a binding buffer containing test compounds, 50 pM [125I]-human calcitonin, media w/o phenol red, 500 ml 0.1% ovalbumin (5 ml 10% ovalbumin) 10 mM Hepes (5 ml 1M) 1× Glutamin (5 ml 100×) 1% P/S (5 ml 100%) Complete (1 tablet/50 ml) 0.1% Pluronic F68®. The morning after, the plates were washed three times in HBSS (4° C.), and lyzed in Lysis buffer (0.1 M NaOH), 1% SDS. Scintillation cocktail (MicroScint40®) was added and the plates were shaken at 500 rpm for a short period. The plate was incubated at room temperature in the dark for 1 hour and Read on a TopCounter™ (Packard). The IC50 was calculated using (one site binding competition analysis) GraphPad Prism5 as a measure of receptor affinity.
The assay was performed as described above (Assay (VII)—Determination of binding to the human calcitonin receptor) with the exception that we used membranes prepared from BHK tk'ts 13 cells that were transiently transfected with the rat calcitonin receptor. The BHK tk'ts 13 cells were transiently transfected with rat calcitonin receptor using FuGENE® 6 (Roche), according to the manufacturer's recommendations. Cells were grown in DMEM with 10% FBS and 1% Pen/Strep. Approximately 48 hours after transfection, the cells were harvested and membranes were prepared.
Assay (IX)—pK—Determination of T½ in Mini-Pig
Pharmacokinetic (PK) studies in Göttingen mini-pigs were conducted in order to determine the T½ of the mimylin compound according to the Examples as indicated after i.v. administration.
T½ values of the amylin analogues of the invention is determined by pharmacokinetic studies in female Göttingen mini-pigs from Ellegaard Göttingen Minipigs ApS and the principles of laboratory animal care are followed.
An acclimatisation period of approximately 6-10 days was allowed before the animals entered the study. At start of the acclimatisation period the mini-pigs were about 5 to 12 months old and in the weight range of 15-35 kg. The mini-pigs had two central venous catheters inserted which were used for blood sampling.
The studies were conducted in an animal room which was illuminated to give a cycle of approximately 12 hours light and 12 hours darkness. The animals were housed individually. The animals had free access to domestic quality drinking water during the study, and no food restrictions applied for PK studies. The animals were weighed on arrival and on the days of dosing.
In the present studies the test substances were administered intravenously in approximately 5 nmol/kg dose. The animals received a single intravenous injection in one central venous catheter and blood sampling was performed from the other catheter, where possible. Each test substance was given to typically three but in some cases two or four animals.
A full plasma concentration-time profile, employing 12-16 sampling points, was obtained from each animal. In example blood samples were collected according to the following schedule:
Pre-dose (0), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168 and 240 hours after injection. In some cases also additional blood samples up to 288 hours post injection were taken.
At each sampling time, 0.5 to 2 ml of blood was drawn from each animal. The blood samples were taken via the central venous catheter.
The 0.8 mL blood samples were collected into EDTA test tubes (8 mM EDTA). Blood samples were kept on ice for max 20 min. before centrifugation. Plasma was separated using centrifugation (i.e. at 4° C., 10 min., 2000G) and was immediately transferred to Micronic tubes on dry ice. Approximately 200 μl plasma was transferred to each Micronic tube. The plasma was stored at −20° C. until assayed. The plasma samples were assayed for the content of compound using LCMS.
The plasma concentration-time profiles were analysed by a non-compartmental pharmacokinetic analysis (NCA) using Phoenix WinNonlin 6.3 (Pharsight Inc., Mountain View, Calif., USA). NCA was performed using the individual plasma concentration-time profiles from each animal. T½ is the terminal half-life=In2/λz and was determined from λz, the first order rate constant associated with the terminal (log-linear) portion of the curve, estimated by linear regression of time vs. log concentration.
40 μl plasma is diluted with 120 μl 66.67% EtOH+1% HCOOH and mixed. Centrifuged for 20 min. at 13000 rpm, 4° C. The supernatant is analyzed by an LC-MS method on a Sciex API 3000 and quantitated with a standard made up in plasma
Assay (X)—pK—Determination of T½ in Rat
Pharmacokinetic (PK) studies rats were conducted in order to determine the T½ of mimylin peptide after i.v. and s.c. administration.
T½ values of the mimylin derivates of the invention is determined by pharmacokinetic studies in Sprague Dawley male rats, from Taconic Europe and the principles of laboratory animal care are followed.
An acclimatisation period of approximately 7 days was allowed before the animals entered the study. At start of the acclimatisation period the rats were in the weight range of 250-400 g.
The studies were conducted in an animal room which was illuminated to give a cycle of approximately 12 hours light and 12 hours darkness. The animals were group housed and had food and water ad lib. The animals were weighed on the days of dosing.
In the present studies the test substances were administered subcutaneously or intravenously in approximately 20 nmol/kg dose. The animals received a single subcutaneous injection to the neck for subtaneous administration or directly into the tail vein for intravenous administration. Each test substance was given to typically three but in some cases two or four animals.
A full plasma concentration-time profile, employing 8-10 sampling points, was obtained from each animal. In example blood samples were collected according to the following schedule: After subcutaneous or intravenous administration:
Predose (0), 0.5, 1, 1.5, 2, 4, 6, 12, 24, 48 and 72 hours after injection.
At each sampling time, 0.08 to 0.10 ml of blood was drawn from each animal. The blood samples were taken in the sublingual vein via venous puncture and the use of a capillary tube.
The blood samples were stabilised with EDTA. Blood samples were kept on ice for max 20 min. before centrifugation. Plasma was separated using centrifugation (i.e. at 4° C., 10 min., 1500G) and was immediately transferred to Micronic tubes or PCR plates. Approximately 40 μl plasma was transferred and was stored at −20° C. until assayed. The plasma samples were assayed for the content of mimylin compound by LCMS
The plasma concentration-time profiles were analysed by a non-compartmental pharmacokinetic analysis (NCA) using Phoenix WinNonlin 6.3 (Pharsight Inc., Mountain View, Calif., USA). NCA was performed using the individual plasma concentration-time profiles from each animal. T½ is the terminal half-life=In2/λz and was determined from λz, the first order rate constant associated with the terminal (log-linear) portion of the curve, estimated by linear regression of time vs. log concentration.
The in-silico study investigated whether the novel peptides sequences that result from protein engineering to generate mimylin analogues could result in peptide sequences capable of binding to major histocompatibility complex class II (MHC-II), also known as HLA-II in humans. Such binding is pre-requisite for the presence of T-cell epitopes. The peptide/HLA-II binding prediction software used in this study was based on two algorithms, NetMHCIIpan 2.1 (Nielsen et al. 2010), performing HLA-DR predictions, and NetMHCII 2.2 (Nielsen et al. 2009) performing HLA-DP/DQ predictions.
It should be noted that there are certain caveats that need to be considered when analysing sequences for MHC class II binding peptides alone, in particular that this method will not account for antigen processing, T cell receptor recognition of the MHC class II/peptide complex or T cell tolerance to any non-germline peptide. Indeed, for these reasons, any analysis of sequences using predictive MHC class II binding tools will result in an over-prediction of the number of actual T cell epitopes.
Any of the HLA-II binding peptides identified in this analysis have the potential to be an active CD4+ T cell epitope although, from the literature it is known that only a minority of such peptides will be actual T cell epitopes when tested in human T cell assays
Nevertheless, any individual promiscuous non-germline HLA-II binding peptide has a risk of being an active CD4+ T cell epitope
Therefore it is recommended that additional assessment is performed using ex vivo T-cell assays to assess their immunogenicity. The results of this ex vivo analysis can be compared to benchmark data on existing protein therapeutics to generate a more accurate pre-clinical assessment of the potential for immunogenicity.
Both wilde-type Salmon calcitonin and the mimylin peptide according to SEQ ID NO: 1 showed no binding prediction for MHC Class II peptides.
SEC-HPLC was conducted using a Waters Insulin HMWP column with isocratic elution (0.5M NaCl, 10 mM NaH2PO4 and 5 mM H3PO4, 50% (v/v) isopropanol) with a flow rate of 0.5 ml/min, a column temperature at 50° C. with UV-detection at 215 nm. Typical column load was one-digit nmol/injection. The total peptide peak area was used as a measure of “total peptide concentration” and absolute total peptide concentration was estimated using UV molar extinctions coefficients calculated based on the primary structure of the individual peptides. The total peptide peak area eluting prior to the monomeric main peak was termed HMWP (High-Molecular-Weight-Protein) and given on a percentage scale relative to the total peptide peak area. The total peptide peak area eluting posterior to the monomeric main peak was termed post-monomer and given on a percentage scale relative to the total peptide peak area.
Before, during and after incubation at specified temperatures one/more of the following examinations are done on a regular basis to assess the quiescent storage stability.
The “total peptide concentration”, HMWP (High-Molecular-Weight-Protein) and post-monomer were determined according to ASSAY (1).
The peptide purity was measured by UPLC using a CSH 1.7 μm, 150×2.1 mm column (60° C.) with UV detection at 215 nm. Eluent A (0.09 di-ammoniumphosphate pH 3.6, 10% MeCN v/v %) and eluent B (80% MeCN v/v %) in a total flow rate of 0.3 ml/min were used (initial: 45% B; 2 min: 45% B; 27 min: 65% B; 28 min: 95% B; 31 min: 95% B; 32 min: 45% B; 35 min: 45% B). Purity was given in % based on the relative area ratio between main peak and total peptide related peak area.
All animal protocols were approved by an Institutional Animal Care and Use Committee and Ethical Review Committee of Novo Nordisk. Diet-induced obese (DIO) male Sprague Dawley rats maintained on a high fat diet (45% kcal fat, RD12451, Research Diets, New Brunswick, N.J., USA) were obtained from Vital River (Beijing, China) and were housed in a temperature (23±2° C.) and light-controlled (12 h:12 h light/dark cycle, lights on at 1800 h) environment with ad libitum access to food and water. Upon arrival, the rats were allowed to acclimate and body weights were monitored on a bi-weekly basis during this period.
Liraglutide was formulated in 8 mM phosphate, 184 mM propylene glycol, 58 mM phenol, pH=8.15. EX. #2 was formulated in 10 mM phosphate, 250 mM glycerol, 0.025% polysorbate 20, pH=7.4; Vehicle-treated animals were dosed with the latter formulation buffer.
Prior to initiation of the study, animals were single-housed and acclimated to handling and injection procedures for 7 days. The DIO rats were distributed into groups (n=10/group) such that statistical variations in the mean and standard deviations of fat mass and body weight were minimized between groups. Animals were dosed once daily, subcutaneously at 16:00 with either vehicle (days 0-28; Group A), liraglutide (0.1 mg/kg days 0-28, Group B), compound of EX. #2 (3.7 μg/kg days 0-28, Group C), or a combination of liraglutide and compound of EX. #2 (0.1 mg/kg liraglutide days 0-28, and 3.7 ug/kg compound of EX. #2 days 15-28; Group D). Body weights were measured immediately prior to dosing each day.
Animals were sacrificed on day 28. Animals were anesthetized with O2/N2O/isoflurane, and blood was taken by cardiac puncture into EDTA tubes, kept on ice and centrifuged within 30 minutes of collection. All EDTA plasma samples were stored at −80° C. thereafter, until analyzed. Liver and brain samples were also collected and stored at −80° C. for later analysis
Assay (XV)—Determination Subcutaneous Mimylin Derivative PK in LYD-Pigs when Co-Formulated with Liraglutide
To determine if co-formulation with liraglutide would change the PK properties of either the mimylin derivatives or liraglutide co-formulation studies were performed in Landrace Yorkshire Duroc crossbreed (LYD) pigs and compared with co-dosing studies.
The studies were performed in female LYD pigs of SPF origin delivered from Lars Jonson, Hillerødvej 70, Lynge.
At start of the acclimatisation period, the body weight of the pigs was in the range of 55-70 kg and the pigs were of app. 5 month of age.
Before the animals arrived, the animal rooms and pens were cleaned and disinfected with Virkon S. During the study, the animal rooms were cleaned and washed regularly.
The pigs were group housed during the acclimatisation period. The pigs were fitted with a central venous catheter while under anaesthesia and after the single housed after catheterization in pens 3.1 m2 with straw as bedding. The temperature in the rooms was set at 20−23° C. and the relative humidity to 30-70%. The rooms were illuminated to give a cycle of 12 hours light and 12 hours darkness. Light was on from 07.00 to 19.00 h.
The subcutaneous formulations used for co-dosing contained either 1.6 mM liraglutide or 1.6 mM mimylin derivative in 8 mM phosphate, 58 mM phenol, 14 mg/ml propylenglycol, pH 8.2. The co-formulation contained 1.6 mM liraglutide and 1.6 mM mimylin derivative in 8 mM phosphate, 58 mM phenol, 14 mg/ml propylenglycol, pH 8.2. The formulations was prepared similarly and filled in cartridges in all cases.
The animals were dosed subcutaneously as follows.
The s.c. dosing was performed in 4 mm depth, in a site of injection which was secured on beforehand by ultrasound to avoid muscular tissue or heavy vascularization. Dosing was made using NovoPen®4 and needle Novofine 28 G and a needle stopper to ensure 4 mm depth of injection. The needle was kept in the subcutis for 10 seconds after the injection to secure deposition of compound. For co-dosing animals received two separate injections on different sides of the neck of liraglutide and Compound 2. The co-formulation was administered as one injection. Study was performed as a cross over study with adequate wash out between dosings. Animals were in all studies dosed with 2 nmol/kg liraglutide and 2 nmol/kg mimylin derivate.
Blood was sampled at predefined time points for up till 15 days post dosing to adequately cover the full plasma concentration-time profile of the mimylin derivative. Blood samples were drawn from a central venous catheter to jugularis made through the catheter which was afterwards flushed with 10 ml 0.9% NaCl.
For each blood sampling time point approximately 0.8 mL of whole blood was collected in a 1.5 mL EDTA coated tube, and the tube was gently turned to allowing mixing of the sample with the anticoagulant. Blood samples (for example 0.8 mL) were collected in EDTA buffer (8 mM) and then centrifuged at 4° C. and 2000 G for 10 minutes. Plasma was pipetted into Micronic tubes on dry ice, and kept at −20° C. until analysis.
The plasma concentration of the respective mimylin derivative was analysed using LC-MS and liraglutide by LOCI. Individual plasma concentration-time profiles were analysed by a non-compartmental model in Phoenix WinNonlin version 6.3 (Pharsight Inc., Mountain View, Calif., USA).
The area under the plasma concentration versus time curve (AUC, [time×concentration]) was calculated (by the Pharsight programme) after subcutaneous administration, typically until 240-288 hours post dosing, or until last measured concentration. The AUC was calculated and given as AUCinf-pred and dose normalized. However, in cases where the extrapoloated area in the profile exceeded 20% then AUClast was used to calculated AUC and dose-normalized.
Results of co-formulation studies in LYD-pigs are summarized below
Pharmacokinetic (PK) studies in Landrace Yorkshire Duroc crossbreed (LYD) pigs were conducted in order to determine a) the protraction of the mimylin derivative after i.v. administration, and b) the bioavailability of the mimylin derivative after s.c. administration The LYD pig were delivered, treated and acclimatised as described in ASSAY XV above.
In the i.v. and s.c. studies, the mimylin derivative was dissolved in 50 mM phosphate, 70 mM sodium chloride and 0.05% polysorbate 80, pH=8.0 to a concentration of approximately 100 nmol/mL. Animals were dosed with 2 nmol/kg s.c. and 5 nmol/kg i.v.
The animals were dosed subcutaneously or intravenously as follows.
The s.c. dosing was performed in 4 mm depth, in a site of injection which was secured on beforehand by ultrasound to avoid muscular tissue or heavy vascularization. Dosing was made using NovoPen®4 and needle Novofine 28 G and a needle stopper to ensure 4 mm depth of injection. The needle was kept in the subcutis for 10 seconds after the injection to secure deposition of compound.
Intravenous administration was performed either by an ear vein or through a venflon.
Blood was sampled at predefined time points for up till 10-12 days post dosing to adequately cover the full plasma concentration-time profile of the mimylin derivative. The remainder followed the protocol as described in ASSAY (XV) blood sampling above,
The plasma concentration of the respective mimylin derivative was analysed using LC-MS. Individual plasma concentration-time profiles were analysed by a non-compartmental model in Phoenix WinNonlin version 6.3 (Pharsight Inc., Mountain View, Calif., USA).
The resulting terminal half-life was determined based on intravenous administration. T½ is the terminal half-life=In2/λz and was determined from λz, the first order rate constant associated with the terminal (log-linear) portion of the curve, estimated by linear regression of time vs. log concentration.
The absolute bioavailability (F) was calculated as follows:
The area under the plasma concentration versus time curve (AUC, [time×concentration]) was calculated (by the Pharsight programme) after both subcutaneous administration and intravenous administration, typically until 240-288 hours post dosing, or until last measured concentration. The AUC was calculated by extrapolating to infinity and dose normalized. The absolute bioavailability (F %) was then calculated based on the dose-corrected AUC values, namely as AUC/Dsc divided by AUC/Div×100, where Dsc is the subcutaneous dose per kg, and Div the dose per kg given intravenously.
Pharmacokinetic (PK) studies in Beagle dogs were conducted in order to determine a) the protraction of the mimylin derivative after i.v. administration, and b) the bioavailability of the mimylin derivative after s.c. administration.
By protraction is meant the prolongation of the time in the body and thereby the time of action of the mimylin derivatives. This was done in PK studies, where the terminal half-life of the derivative in question was determined following i.v. administration. By terminal half-life is generally meant the period of time it takes to halve a certain plasma concentration, measured after the initial distribution phase.
The mimylin compound was subjected to PK studies as described below.
For the studies with the mimylin derivative Compound 2 the Beagle dogs were 1 to 5 years of age and weighing approximately 10-12 kg at the start of the studies. The dogs were group housed in pens (12 hours light: 12 hours dark), and fed individually and restrictedly once daily with Royal Canin Medium Adult dog (Royal Canin Products, Brogaarden A/S, Denmark). Exercise and group social was permitted daily, whenever possible. The dogs were used for repeated pharmacokinetic studies with a suitable wash-out period between dosings. An appropriate acclimatisation period was given prior to initiation of the first pharmacokinetic study. All handling, dosing and blood sampling of the animals was performed by trained and skilled staff. Before the studies the dogs were fasted overnight and from 0 to 4 h after dosing. Besides, the dogs were restricted to water 1 hour before dosing until 4 hours after dosing, but otherwise had ad libitum access to water during the whole period.
In the i.v. and s.c. studies, the mimylin derivative, dissolved 10 mM phosphate; 250 mM glycerol; 0.025% polysorbate 20, pH=7.4, to a concentration of approximately 10 nmol/ml (i.v.) and 50 nmol/ml (s.c.), were administered to the dogs by intravenous or subcutaneous injections (the volume corresponding to 1-5 nmol/kg, for example 0.1-0.2 ml/kg) in the cephalic or in subcutaneously in the dorsal part of the neck.
Blood was sampled at predefined time points for up till 10-12 days post dosing to adequately cover the full plasma concentration-time profile of the mimylin derivative.
For each blood sampling time point approximately 0.8 mL of whole blood was collected in a 1.5 mL EDTA coated tube (8 mM), and the tube was gently turned to allowing mixing of the sample with the anticoagulant, and then centrifuged at 4° C. and 1942 G for 4 minutes. Plasma was pipetted into Micronic tubes on dry ice, and kept at −20° C. until analysis.
Blood samples were taken as appropriate, for example a) from the jugular vein using a standard 21G needle and a syringe, or b) from a venflon in the cephalic vein in the front leg for the first 2 hours and then with syringe from the jugular vein for the rest of the time points (the first few drops were allowed to drain from the venflon to avoid heparin saline from the venflon in the sample).
The plasma concentration of the respective mimylin derivative was analysed using LC-MS. Individual plasma concentration-time profiles were analysed by a non-compartmental model in Phoenix WinNonlin version 6.3 (Pharsight Inc., Mountain View, Calif., USA).
The resulting terminal half-life was determined based on intravenous administration. T½ is the terminal half-life=In2/λz and was determined from λz, the first order rate constant associated with the terminal (log-linear) portion of the curve, estimated by linear regression of time vs. log concentration.
The absolute bioavailability (F) was calculated as follows:
The area under the plasma concentration versus time curve (AUC, [time x concentration]) was calculated (by the Pharsight programme) after both subcutaneous administration and intravenous administration, typically until 240-288 hours post dosing, or until last measured concentration. The AUC was calculated by extrapolating to infinity and dose normalized. The absolute bioavailability (F %) was then calculated based on the dose-corrected AUC values, namely as AUC/DSc divided by AUC/Div×100, where Dsc is the subcutaneous dose per kg, and Div the dose per kg given intravenously.
Aqueous formulations are prepared by mixing aqueous stock solutions containing well-defined concentrations of excipients (antimicrobial agent, tonicity agent, pH buffer) with an aqueous stock solution containing a well-defined concentration of mimylin peptide and/or a GLP-1 compound. Alternatively, the mimylin peptide is dissolved directly in an aqueous solution containing well-defined concentrations of excipients and a GLP-1 compound. Following pH-adjustment, each formulation is sterile filtered (0.22 μm filter) to sterile glass containers.
Formulations containing 0.8 mM compound of EX. #40 or 0.8 mM compound of EX. #46 were prepared according to Example A. All formulations contained 8 mM phosphate and were pH-adjusted to pH 8.2. An additional set of formulations also containing 58 mM phenol and 14 mg/ml propylene glycol were prepared. Each formulation was tested according to ASSAY (IIIa).
Each formulation was tested according to ASSAY (XIII), and the results are presented below.
£HMWP after 8 weeks at 37° C.
$Post monomer after 8 weeks at 37° C. minus start value
Purity loss in %/month at 37° C.
Formulations containing 0.5 mM compound of EX. #40 or 0.5 mM compound of EX. #46 were prepared according to Example A. All formulations contained 10 mM phosphate and were pH-adjusted to pH 7.4 or pH 8.2. An additional set of formulations also containing 50 mM NaCl and/or 50 mM phenol were prepared. Total peptide concentration was measured after 4-5 days storage at 5° C. or at room temperature.
Four formulations containing 0.3 mM or 0.03 mM compound of EX. #46 were prepared according to Example A. All formulations contained 16 mg/ml glycerol and pH was adjusted to pH 7.4. On top of that, two of the formulations contained 19 mM phenol, 19 mM m-cresol, 5 mM phosphate, 20 mM NaCl and the other two formulations contained 28 mM m-cresol. All formulations were tested according to ASSAY (IIIa).
Formulations containing 0.2 mM compound of EX. #40 were prepared according to Example A. All formulations contained 8 mM phosphate pH was adjusted to pH 8.2. On top of that, four of the formulations contained increasing concentration of propylene glycol (10-20-50-100 mg/ml) whereas four other formulations contained increasing concentration of glycerol (10-20-50-100 mg/ml). All formulations were tested according to ASSAY (XII) before and after 4 weeks storage at 5° C. and 37° C.
Formulations containing compound of EX. #2 were prepared according to Example A and tested according to ASSAY (IIIa).
Formulations containing variable concentrations of compound of EX. #2 were prepared according to Example A. All formulations contained 14 mg/ml propylene glycol, 58 mM phenol and 8 mM phosphate. pH was adjusted to specific levels between pH 6.6 and pH 8.6. All formulations were tested according to ASSAY (XIII).
£% HMWP after 11 weeks at 37° C. (Formulation F74-F79) or HMWP formation rate (%/month) at 37° C. (Formulation F80-F85)
$Post monomer after 11 weeks at 37° C. minus start value
Purity loss in %/month at 37° C.
Formulations containing 0.05 to 2 mM compound of EX. #2 were prepared according to Example A. All formulations contained 14 mg/ml propylene glycol, 58 mM phenol and 8 mM phosphate, pH 8.2. All formulations were tested according to ASSAY (XIII).
£HMWP after 8 weeks at 37° C.
$Post monomer after 8 weeks at 37° C. minus start value (nd = not possible to detect)
Purity loss in %/month at 37° C.
Formulations containing 0.01 to 0.5 mM compound of EX. #2 were prepared according to Example A. All formulations contained 14 mg/ml propylene glycol, 58 mM phenol and 8 mM phosphate, pH 8.2. All formulations were tested according to ASSAY (XIII).
Purity loss in %/month at 37° C.
Formulations containing 2.7 pM to 2.7 mM compound of EX. #2 were prepared according to Example A. All formulations contained 14 mg/ml propylene glycol, 58 mM phenol and 8 mM phosphate, pH 7.4. All formulations were tested according to ASSAY (XIII).
£HMWP after 11 weeks at 37° C.
Purity loss in %/month at 37° C.
Formulations containing a compound of EX. #2 were prepared according to Example A and tested according to ASSAY (XIII).
£HMWP after one month at 37° C.
$Post monomer after one month at 37° C. minus start value
Co-formulations containing a compound of EX. #2 and liraglutide were prepared according to Example A together with mono-formulations containing the same amount of the two peptide components. All formulations (mono- and co-) were tested according to ASSAY (IIIa) and ASSAY (XIII).
a1 mg/ml EX. # 2 ~0.27 mM; 1 mg/ml liraglutide ~0.27 mM
£HMWP formation rate at 37° C. (%/month)
#UV-215 nm detection; not baseline separated from liraglutide
UV-280 nm detection
Co-formulations containing compound of EX. #2 and semaglutide were prepared according to Example A together with mono-formulations containing the same amount of the two peptide components. All formulations (mono- and co-) were tested according to ASSAY (IIIa) and ASSAY (XIII).
a1 mg/ml EX. # 2 ~0.27 mM; 1 mg/ml semaglutide ~0.24 mM
£HMWP formation rate at 37° C. (%/month)
$Total peptide recovery reflects the recovery of EX. # 2 and semaglutide in total (EX. # 2 co- elutes with semaglutide)
UV-280 nm detection of semaglutide
Monotherapy with liraglutide and compound of EX. #2 induced a 5.9% and 10.9% reduction in body weight at the given doses, respectively. Addition of compound EX. #2 on day 15 to the treatment regimen with liraglutide caused an additional 9.7% reduction in body weight by day 28 relative to monotherapy with liraglutide. See
a-dp < 0.05, one-way ANOVA and Tukey's multiple comparison test for each day; groups not connected by the same letter (in each column) are significantly different from each other.
Number | Date | Country | Kind |
---|---|---|---|
14183551.2 | Sep 2014 | EP | regional |
This application is continuation of International Application PCT/EP2015/069996 (WO 2016/034604), filed Sep. 2, 2015, which claims priority to European Patent Application EP 14183551.2, filed Sep. 4, 2014; the contents of all above-named applications are incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
Parent | PCT/EP2015/069996 | Sep 2015 | US |
Child | 15151093 | US |